Statera Biopharma (STAB) 10-K 23 Feb 16 2015 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2015	Feb. 12, 2016	Jun. 30, 2015
Document And Entity Information [Abstract]
Entity Registrant Name	CLEVELAND BIOLABS INC
Trading Symbol	CBLI
Entity Central Index Key	1,318,641
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Document Type	10-K
Document Period End Date	Dec. 31, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	FY
Amendment Flag	false
Entity Common Stock, Shares Outstanding		10,987,166
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Public Float			$ 13,983,177

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 5,918,424	$ 3,103,969
Short-term investments	13,701,273	0
Accounts receivable	631,084	267,199
Other current assets	442,642	174,179
Total current assets	20,693,423	3,545,347
Equipment, net	122,958	244,537
Restricted cash	37,663	1,699,759
Other long-term assets	26,560	56,131
Investment in Incuron, LLC	0	4,268,458
Total assets	20,880,604	9,814,232
Current liabilities:
Accounts payable	197,134	1,057,743
Accrued expenses	1,584,826	1,804,456
Deferred revenue	11,892	156,317
Accrued warrant liability	4,048,900	862,074
Current portion of notes payable	0	2,640,968
Current portion of capital lease obligation	0	7,522
Total current liabilities	5,842,752	6,529,080
Noncurrent portion of capital lease obligation	0	0
Long-term debt	0	1,499,050
Commitments and contingencies	0	0
Total liabilities	5,842,752	8,028,130
Stockholders’ equity:
Preferred stock, $.005 par value; 10,000,000 shares authorized, 0 shares issued and outstanding as of December 31, 2015 and 2014, respectively	0	0
Common stock, $.005 par value; 160,000,000 shares authorized,10,987,166 and 2,858,126 shares issued and outstanding as of December 31, 2015 and 2014, respectively	54,932	14,287
Additional paid-in capital	158,764,985	132,693,988
Other comprehensive income/(loss)	(408,051)	(380,110)
Accumulated deficit	(147,978,831)	(133,935,562)
Treasury Stock, at cost; 158,900 and 0, respectively	(544,853)	0
Total Cleveland BioLabs, Inc. stockholders’ equity/(deficit)	9,888,182	(1,607,397)
Noncontrolling interest in stockholders’ equity	5,149,670	3,393,499
Total stockholders’ equity	15,037,852	1,786,102
Total liabilities and stockholders’ equity	$ 20,880,604	$ 9,814,232

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2015	Dec. 31, 2014
Statement of Financial Position [Abstract]
Preferred stock, par value ($ per share)	$ 0.005	$ 0.005
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value ($ per share)	$ 0.005	$ 0.005
Common stock, authorized (shares)	160,000,000	160,000,000
Common stock, issued (shares)	10,987,166	2,858,126
Common stock, outstanding (shares)	10,987,166	2,858,126
Treasury stock, (shares)	158,900	0

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Revenues:
Grants and contracts	$ 2,708,225	$ 3,701,899
Operating expenses:
Research and development	7,143,293	9,654,144
General and administrative	6,355,962	8,469,690
Total operating expenses	13,499,255	18,123,834
Loss from operations	(10,791,030)	(14,421,935)
Other income (expense):
Interest and other expense	(99,488)	(1,089,582)
Foreign exchange loss	(509,513)	(1,036,459)
Investment loss provision	(1,060,834)	0
Gain on deconsolidation of Incuron, LLC	0	14,206,555
Change in value of warrant liability	(221,915)	2,662,329
Equity in loss of Incuron, LLC	(362,137)	(285,542)
Total other income	(2,253,887)	14,457,301
Net income (loss)	(13,044,917)	35,366
Net loss attributable to noncontrolling interests	407,280	1,593,738
Net income (loss) attributable to Cleveland BioLabs, Inc.	$ (12,637,637)	$ 1,629,104
Net income (loss) available to common stockholders per share of common stock, basic and diluted (per share)	$ (1.79)	$ 0.60
Weighted average number of shares used in calculating net income (loss) per share, basic and diluted (shares)	7,060,396	2,702,884

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income (Loss) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Statement of Comprehensive Income [Abstract]
Net income (loss) including noncontrolling interests	$ (13,044,917)	$ 35,366
Other comprehensive loss
Unrealized loss on short-term investments	(6,190)	0
Foreign currency translation adjustment	30,025	(1,816,840)
Comprehensive loss including noncontrolling interests	(13,021,082)	(1,781,474)
Comprehensive loss attributable to noncontrolling interests	449,752	2,477,469
Comprehensive income (loss) attributable to Cleveland BioLabs, Inc.	$ (12,571,330)	$ 695,995

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Cash flows from operating activities:
Net income (loss)	$ (13,044,917)	$ 35,366
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation	140,135	200,792
Amortization of loan costs	135,082	640,248
Gain on debt extinguishment	(184,475)	0
Unrealized currency loss on short-term investments	(17,928)	0
(Gain) loss on equipment disposal	(25,685)	24,685
Investment loss provision	1,060,834	0
Noncash compensation	96,401	496,470
Warrant issuance costs	617,776	171,116
Equity in loss of Incuron, LLC	362,137	285,542
Change in value of warrant liability	221,915	(2,662,329)
Gain on deconsolidation of Incuron, LLC	0	(14,206,555)
Changes in operating assets and liabilities:
Accounts receivable	(414,068)	629,397
Other current assets	(286,240)	(1,243)
Other long-term assets	13,431	15,690
Accounts payable	(833,947)	459,337
Deferred revenue	(130,048)	(756,808)
Accrued expenses	209,477	213,104
Net cash used in operating activities	(12,080,120)	(14,455,188)
Cash flows from investing activities:
Purchase of short-term investments	(16,873,917)	(1,408,169)
Sale of short-term investments	3,184,287	1,689,670
Purchase of equipment	5,910	(20,222)
Proceeds from sale of Incuron, LLC	3,000,000	0
Cash divested upon deconsolidation of Incuron, LLC	0	(2,048,023)
Decrease in restricted cash	407,097	0
Net cash used in investing activities	(10,276,623)	(1,786,744)
Cash flows from financing activities:
Issuance of common stock, net of offering costs	27,190,292	9,697,501
Net repayment of long-term debt	(2,664,691)	(4,176,275)
Noncontrolling interest capital contribution to Incuron, LLC	0	5,152,438
Net proceeds from sale of treasury stock	417,545	0
Repayment of capital lease obligation	(7,522)	(83,634)
Net cash provided by financing activities	24,935,624	10,590,030
Effect of exchange rate change on cash and equivalents	235,574	(1,292,595)
Increase (Decrease) in cash and cash equivalents	2,814,455	(6,944,497)
Cash and cash equivalents at beginning of period	3,103,969	10,048,466
Cash and cash equivalents at end of period	5,918,424	3,103,969
Supplemental disclosure of cash flow information:
Cash paid during the period for interest	517,904	451,327
Supplemental schedule of noncash financing activities:
Debt to equity conversion	1,846,200	0
Repurchase of treasury stock	906,321	0
Noncash warrant issuance costs	0	15,993
Warrants
Supplemental schedule of noncash financing activities:
Allocation of equity proceeds to fair value of warrants	$ 3,081,634	$ 2,216,593

Consolidated Statement of Stock

Consolidated Statement of Stockholders' Equity - USD ($)	Total	Common Stock	Treasury Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit	Noncontrolling Interests
Beginning balance at Dec. 31, 2013	$ 1,580,978	$ 11,299	$ 0	$ 125,723,083	$ 307,339	$ (135,564,666)	$ 11,103,923
Beginning balance (in shares) at Dec. 31, 2013		2,259,818	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock based compensation (in shares)		3,052
Stock based compensation	645,500	$ 12		645,488
Issuance of common stock, net of offering cost (in shares)		595,256
Issuance of common stock, net of offering costs	9,802,118	$ 2,976		9,799,142
Allocation of equity proceeds to fair value of warrants	(2,216,593)			(2,216,593)
Noncontrolling interest capital contribution	5,152,283			1,176,982			3,975,301
Deconsolidation of Incuron, LLC	(11,396,710)			(2,434,114)	245,660		(9,208,256)
Net income (loss)	35,366					1,629,104	(1,593,738)
Unrealized gain on short-term investments	0
Foreign currency translation	(1,816,840)				(933,109)		(883,731)
Ending balance at Dec. 31, 2014	1,786,102	$ 14,287		132,693,988	(380,110)	(133,935,562)	3,393,499
Ending balance (in shares) at Dec. 31, 2014		2,858,126
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock based compensation (in shares)		5,023
Stock based compensation	256,820	$ 25		256,795
Issuance of common stock, net of offering cost (in shares)		8,122,189
Issuance of common stock, net of offering costs	28,880,473	$ 40,611		28,839,862
Repurchase of Treasury Stock (in shares)			264,318
Repurchase of Treasury Stock	$ (906,321)		$ (906,321)
Sale of Treasury Stock (in shares)	(105,418)		(105,418)
Sale of Treasury Stock	$ 417,545		$ 361,468	56,077
Exercise of Warrants (in shares)		1,828
Exercise of warrants		$ 9		(9)
Allocation of equity proceeds to fair value of warrants	(3,081,634)			(3,081,634)
Increased ownership of Panacela Labs, Inc.	(94)			(94)	(94,248)	(1,405,632)	1,499,880
Noncontrolling interest capital contribution	706,043						706,043
Net income (loss)	(13,044,917)					(12,637,637)	(407,280)
Unrealized gain on short-term investments	(6,190)				(6,190)
Foreign currency translation	30,025				72,497		(42,472)
Ending balance at Dec. 31, 2015	$ 15,037,852	$ 54,932	$ (544,853)	$ 158,764,985	$ (408,051)	$ (147,978,831)	$ 5,149,670
Ending balance (in shares) at Dec. 31, 2015		10,987,166	158,900

Consolidated Statement of Stoc8

Consolidated Statement of Stockholders' Equity (Parenthetical) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Common Stock
Offering costs	$ 1,410,011	$ 697,882

Description of Business

Description of Business	12 Months Ended
	Dec. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business	Description of Business Cleveland BioLabs, Inc. (" CBLI " or the " Company ") is an innovative biopharmaceutical company developing novel approaches to activate the immune system and address serious medical needs. Our proprietary platform of Toll-like immune receptor activators has applications in radiation mitigation and immuno-oncology. We combine our proven scientific expertise and our depth of knowledge about our products’ mechanisms of action into a passion for developing drugs to save lives. Our most advanced product candidate is entolimod, an immune-stimulatory agent, which we are developing as a radiation countermeasure and an immunotherapy for oncology and other indications. CBLI was incorporated in Delaware in June 2003 and is headquartered in Buffalo, New York. CBLI conducts business in the United States (" U.S. ") and in the Russian Federation (" Russia "), through several subsidiaries including: one wholly-owned subsidiary, BioLab 612, LLC ("BioLab 612 "), which began operations in 2012; Panacela Labs, Inc. (" Panacela "), which was formed by us and Open Joint Stock Company “Rusnano” (" Rusnano ") our financial partner, in 2011; and, Incuron LLC (" Incuron "), which was formed by us and Bioprocess Capital Ventures (" BCV ") our financial partner, in 2010. As more fully described in Note 5, "Noncontrolling Interests" our ownership in Incuron has decreased during the two years ended December 31, 2015 from being the majority shareholder until November 25, 2014, to longer being a shareholder as of June 30, 2015. Unless otherwise noted, references to the “Company,” “we,” “us” and “our” refer to Cleveland BioLabs, Inc. together with its subsidiaries.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Basis of Presentation and Consolidation The accompanying consolidated financial statements include the accounts of CBLI and the subsidiaries in which CBLI held a controlling interest as of and for the periods presented. The accounts of Incuron are included through November 25, 2014, the date at which CBLI no longer maintained a controlling interest. For the period from November 25, 2014 through April 29, 2015, the Company’s interest in Incuron has been presented under the equity method of accounting, with the completed sale of our entire equity interests in Incuron recorded in the quarter ended June 30, 2015. All significant intercompany balances and transactions have been eliminated. These financial statements have been prepared on the accrual basis in accordance with accounting principles generally accepted in the United States (" GAAP "). On January 28, 2015, the Company, after receiving authorization from the Company’s shareholders and board of directors, executed a reverse stock split, or Reverse Split, of the Company’s common stock at the ratio of 1:20. All historical share balances and share price-related data have been adjusted based on this ratio. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Cash and Cash Equivalents Of the $5.9 million and $3.1 million of cash and cash equivalents at December 31, 2015 and December 31, 2014 , respectively, $1.9 million and $0.0 million , respectively, consisted of highly liquid investments with maturities of 90 days or less when purchased. These investments consist of U.S. Treasury securities, time deposits and investments in money market funds with commercial banks and financial institutions. As of December 31, 2015 , $1.2 million of the Company’s cash and cash equivalents were held in Russian banks, of which $1.1 million was denominated in rubles with the remaining $0.1 million denominated in U.S. dollars. Short-Term Investments The Company’s short-term investments are classified as available for sale. Accordingly, these investments are carried at fair market value. Short-term investments consisted primarily of U.S. Treasury securities. Unrealized gains and losses on available for-sale investments are reported as Other Comprehensive Loss, a separate component of stockholders’ equity. Realized gains and losses, and interest and dividends on available-for-sale securities are recorded in our Consolidated Statement of Operations as "Interest and Other Income." The cost of securities sold is based on the specific identification method. All of the Company's short-term investments were held in U.S. financial institutions. Concentrations of Credit Risk Financial instruments that potentially subject the Company to a significant concentration of credit risk primarily consist of cash and cash equivalents and short-term investments. The Company maintains cash balances with financial institutions in excess of insured limits. With the exception of our deposits at NOTA-Bank, discussed in "Restricted Cash" below, the Company does not believe it is exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. As of December 31, 2015 , the Company held 21% of its cash and cash equivalents in accounts located outside of the United States. As of February 12, 2016, the Russian Ruble: Dollar exchange rate increased from 72.8827 to 79.1144 , resulting in a decrease of $(87.1) thousand to the Company’s cash and cash equivalents as compared to December 31, 2015 . Significant Customers and Accounts Receivable The following table presents our revenue by customer, on a proportional basis, for the periods indicated: Years ended December 31, 2015 2014 Variance U.S. Department of Defense 7.9 % 0.6 % 7.3 % Russian government agencies 59.6 % 95.2 % (35.6 )% Incuron, LLC 32.5 % 4.2 % 28.3 % 100.0 % 100.0 % — % Although the Company anticipates ongoing contract and grant revenue from these customers, there is no guarantee that these revenue streams will continue in the future. The Company extends unsecured credit to its government customers under normal trade agreements and contracted terms, which generally require payment within 30 days . Accounts receivable consist of amounts due under contracts and grants from these customers, along with amounts receivable under subleases at our Buffalo, New York office facility. There were allowances for doubtful accounts of $0.2 and $0.1 million at December 31, 2015 and December 31, 2014 , respectively, pertaining to accounts receivable from our subleases. Equipment Equipment is stated at cost, net of accumulated depreciation. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is credited or charged to operations. Repair and maintenance costs are expensed as incurred. Equipment is depreciated using the straight-line method over the estimated useful lives of the respective assets as follows: Asset Category Estimated Useful Life (in Years) Laboratory equipment 5 Furniture and fixtures 5 Computer equipment 3 Impairment of Long-Lived Assets Long-lived assets to be held and used are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amounts of the assets or related asset group may not be recoverable. Determination of recoverability is based on an estimate of discounted future cash flows resulting from the use of the asset. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the asset or asset group, the carrying amount of the asset is written down to its estimated net realizable value. Restricted Cash Restricted cash at December 31, 2015 includes certificates of deposit denominated in Russian rubles and posted by Panacela and BioLab 612 as collateral for performance guarantees for their contracts with the Ministry of Industry and Trade of the Russian Federation. The guarantees require Panacela and BioLab 612 to satisfactorily perform their statements of work under the contracts, after which the requirement for these deposits will be released. Both Panacela and BioLab 612 anticipate satisfactory contract performance with the release of funds processed in 2017. As a consequence, all of the Company’s restricted cash is classified as a noncurrent asset. Some of our restricted cash is on deposit at NOTA-Bank. We previously disclosed that the Bank of Russia appointed temporary management of NOTA-Bank and placed a three-month moratorium on all creditor claims. Subsequently, on November 24, 2015, the bank’s license was revoked by the Bank of Russia, and on January 19, 2016, the Moscow Arbitration Court declared NOTA-Bank insolvent, noting a 70% deficiency in assets. As a result of these developments, the absence of deposit insurance coverage available to Panacela and the fact that what assets do remain will need to be settled according to priorities established by Russian law (i.e., corporate depositors are satisfied after individual depositors and state-sponsored organizations), we have written off the full value of our deposits with NOTA-Bank, aggregating $1,060,834 , which was recorded as "Investment Loss Provision" on the Statement of Operations for the year ended December 31, 2015. The remaining amount of "Restricted Cash" at December 31, 2015 , is on deposit with other banking institutions. If and when we recover deposits from NOTA-Bank, we will record a gain at that time. Equity Method Investment The Company’s equity method investment, reported as of December 31, 2014, included its minority holdings in Incuron. The opening equity investment amount as of November 25, 2014, the date at which we no longer maintained a controlling interest, was determined to be $4,554,000 and represented an ownership interest in Incuron of 46.96% . This determination was made by an independent valuation expert based on the commercial potential of Incuron’s drug candidates and market values assigned to other early-stage oncology drug candidates. Under the equity method, the carrying amount of the investment is adjusted for the Company’s share of earnings and losses, as well as any capital contributions to and distributions from Incuron. The Company classifies income and losses related to its equity method investments as a component of operating income or loss as Incuron is an extension of the Company’s core business. Intellectual Property Costs related to filing and pursuing patent applications are recognized as general and administrative expenses as incurred, since the recoverability of such expenditures is uncertain. Upon marketability approval by the U.S. Food and Drug Administration (" FDA "), or a respective foreign governing body, such costs will be capitalized and depreciated over the expected life of the related patent. Deferred Revenue Deferred revenue represents cash received under grants and contracts in excess of the revenue recognizable through the end of the respective financial reporting period. The revenue associated with these advances will be recognized in future periods as the applicable costs are incurred. Accrued Warrant Liability Certain warrants are accounted for as derivative instruments in accordance with the Financial Accounting Standards Board Accounting Standards Codification (the " Codification "), on derivatives and hedging as the warrant holders, under certain change of control situations, could require settlement in cash. As such, the warrants were initially recorded as liabilities based on their fair values on the date of issuance. Subsequent changes in the value of the warrants are recorded in the Statements of Operations as “Change in value of warrant liability.” The Company’s remaining outstanding warrants were treated as equity upon issuance and continue to be treated as equity since they did not contain any mandatory redemption features or other provisions that would require a different classification of these warrant instruments outside of permanent equity. Foreign Currency Translation The Russian ruble is the functional currency of our foreign subsidiaries, which are all located in the Russian Federation. Assets and liabilities of these companies are translated into U.S. dollars at the period-end exchange rate. Income and expense items are translated at the average exchange rates during the period. The net effect of this translation is recorded in the consolidated financial statements as accumulated other comprehensive income (loss). Other Comprehensive Income/(Loss) The Company applies the Codification on comprehensive income (loss) that requires disclosure of all components of comprehensive income (loss) on an annual and interim basis. Comprehensive income (loss) is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. The following table presents the changes in accumulated other comprehensive loss for the year ended December 31, 2015 . Unrealized loss on available-for-sale securities Gains and losses on foreign exchange translations Total Beginning balance $ — $ (380,110 ) $ (380,110 ) Other comprehensive income/(loss) before reclassifications (6,190 ) 30,025 23,835 Amounts reclassified from accumulated other comprehensive loss — (51,776 ) (51,776 ) Ending balance $ (6,190 ) $ (401,861 ) $ (408,051 ) Revenue Recognition The Company generates grant and contract revenue from two different types of contractual arrangements: cost reimbursable grants and contracts and fixed-price grants and contracts. Costs consist primarily of internal labor charges, subcontractors and materials, as well as an allocation of fringe benefits, overhead and general and administrative expenses, based on the terms of the contract. Under cost reimbursable grants and contracts, revenue is recognized during the period that the associated research and development costs are incurred. Under fixed-price grants and contracts, revenue is recognized using the percentage-of-completion method. The assumptions and estimates used in determination of the percentage-of-completion are developed in coordination with the principal investigator performing the work. Research and Development Research and development (" R&D ") costs are expensed as incurred. R&D costs primarily consist of salaries, fringe benefits, and stock-based compensation for our clinical and scientific personnel along with a ratable share of our facility expenses. Other R&D expenses include fees paid to research-oriented consultants and outside service providers, and the costs of materials used in clinical trials and other research activities. Accounting for Stock-Based Compensation The 2006 Equity Incentive Plan, as amended (the “ Plan ”), authorizes CBLI to grant (i) options to purchase common stock, (ii) restricted or unrestricted stock units, and (iii) stock appreciation rights, so long as the exercise or grant price of each are at least equal to the fair market value of the stock on the date of grant. At the 2015 annual meeting of stockholders, an amendment to increase the maximum number of shares of common stock reserved for issuance under the Plan was approved, and as of December 31, 2015 , an aggregate of 650,000 shares of common stock were authorized for issuance under the Plan, of which a total of approximately 180,476 shares of common stock remained available for future awards. A single participant cannot be awarded more than 100,000 shares annually. Awards granted under the Plan have a contractual life of no more than 10 years . The terms and conditions of equity awards (such as price, vesting schedule, term and number of shares) under the Plan are specified in an award document, and approved by compensation committee of the CBLI board of directors. The Company utilizes the Black-Scholes valuation model for estimating the fair value of all stock options granted. Set forth below are the assumptions used in valuing the stock options granted and a discussion of the Company’s methodology for developing each of the assumptions used: For the year ended December 31, 2015 2014 Risk-free interest rate 1.35-1.59% 1.59 - 1.98% Expected dividend yield 0% 0% Expected life 5 - 5.5 Years 5 - 6 Years Expected volatility 75.53-76.21% 71.24 - 78.02% “Risk-free interest rate” means the range of U.S. Treasury rates with a term that most closely resembles the expected life of the option as of the date the option is granted. “Expected dividend yield” means the Company does not pay regular dividends on its common stock and does not anticipate paying any dividends in the foreseeable future. “Expected life” means the period of time that options granted are expected to remain outstanding, based wholly on the use of the simplified (safe harbor) method. The simplified method is used because the Company does not yet have adequate historical exercise information to estimate the expected life the options granted. “Expected volatility” means a measure of the amount by which a financial variable, such as share price, has fluctuated (historical volatility) or is expected to fluctuate (implied volatility) during a period. Expected volatility is based on the Company’s historical volatility and incorporates the volatility of the common stock of comparable companies when the expected life of the option exceeds the Company’s trading history. In June 2013, CBLI’s stockholders approved the 2013 Employee Stock Purchase Plan (" ESPP "), which provides a means by which eligible employees of CBLI, and certain designated related corporations may be given an opportunity to purchase shares of CBLI common stock. As of December 31, 2015 , there were 225,000 shares of common stock reserved for purchase under the ESPP. The number of shares reserved for purchase under the ESPP increases on January 1 of each calendar year by the lesser of (i) 10% of the total number of shares of common stock outstanding on December 31 of the preceding year, or (ii) 100,000 shares of common stock. The ESPP, when implemented, will allow employees to use up to 15% of their compensation, up to $25,000 per year, to purchase shares of common stock at an amount equal to 85% of the fair market value of the our common stock on the offering date or the purchase date, whichever is less. Income taxes No income tax expense was recorded for the years ended December 31, 2015 , and 2014 , as the Company did not have taxable income for any of the years presented. A full valuation allowance has been recorded against the Company’s net deferred tax asset. Earnings/(loss) per share Basic net income (loss) per share of common stock excludes dilution for potential common stock issuances and is computed by dividing net income (loss) by the weighted average number of shares outstanding for the period. Diluted net income (loss) per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock. Diluted net loss per share is identical to basic net loss per share as potentially dilutive securities have been excluded from the calculation of diluted net loss per common share because the inclusion of such securities would be antidilutive. The Company has excluded the following outstanding warrants and options from the calculation of diluted net loss per share because all such securities were antidilutive for the periods presented: As of December 31, Common Equivalent Securities 2015 2014 Warrants 2,222,155 875,304 Options 343,643 261,389 Total 2,565,798 1,136,693 Recently Issued Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board or other standard setting bodies that are adopted by us as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our financial position or results of operations upon adoption. In January 2016, the FASB issued ASU 2016-01, "Financial Instruments - Overall: Recognition and Measurement of Financial Assets and Financial Liabilities." The pronouncement requires equity investments (except those accounted for under the equity method of accounting, or those that result in consolidation of the investee) to be measured at fair value with changes in fair value recognized in net income, requires public business entities to use the exit price notion when measuring the fair value of financial instruments for disclosure purposes, requires separate presentation of financial assets and financial liabilities by measurement category and form of financial asset, and eliminates the requirement for public business entities to disclose the method(s) and significant assumptions used to estimate the fair value that is required to be disclosed for financial instruments measured at amortized cost. These changes become effective for the Company's fiscal year beginning January 1, 2018. The expected adoption method of ASU 2016-01 is being evaluated by the Company and the adoption is not expected to have a significant impact on the Company’s consolidated financial position or results of operations. In May 2015, the FASB issued ASU 2015-08, Business Combinations - Pushdown Accounting - Amendment to SEC Paragraphs Pursuant to Staff Accounting Bulletin No. 115. This Update was issued to amend various SEC paragraphs pursuant to the issuance of Staff Accounting Bulletin No. 115. This ASU is not expected to have a significant impact on the Company’s financial statements. In November 2014, the FASB issued ASU 2014-17, Business Combinations (Topic 805): Pushdown Accounting. The amendments in this Update apply to the separate financial statements of an acquired entity and its subsidiaries that are a business or nonprofit activity (either public or nonpublic) upon the occurrence of an event in which an acquirer (an individual or an entity) obtains control of the acquired entity. An acquired entity may elect the option to apply pushdown accounting in the reporting period in which the change-in-control event occurs. If pushdown accounting is not applied in the reporting period in which the change-in-control event occurs, an acquired entity will have the option to elect to apply pushdown accounting in a subsequent reporting period to the acquired entity's most recent change-in-control event. The amendments in this Update were effective on November 18, 2014. After the effective date, an acquired entity can make an election to apply the guidance to future change-in-control events or to its most recent change-in-control event. This ASU is not expected to have a significant impact on the Company’s financial statements. In May 2014, the Financial Accounting Standards Board (" FASB "), issued Accounting Standards Update (" ASU, 2014-9 "), Revenue from Contracts with Customers, which updates the principles for recognizing revenue. ASU 2014-9 also amends the required disclosures of the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. ASU 2014-9 is effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. The Company is evaluating the potential impacts of the new standard on its existing revenue recognition policies and procedures. In August 2014, the FASB issued ASU 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (" ASU 2014-15 ") requires that an entity’s management evaluate whether there are conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued. ASU 2014-15 is effective for annual periods beginning after December 15, 2016 and for interim periods thereafter. The Company is evaluating the potential impacts of this new standard on its quarterly reporting process.

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2015
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements The Company measures and records cash equivalents and warrant liabilities at fair value in the accompanying financial statements. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability, an exit price, in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value include: • Level 1 – Observable inputs for identical assets or liabilities such as quoted prices in active markets; • Level 2 – Inputs other than quoted prices in active markets that are either directly or indirectly observable; and • Level 3 – Unobservable inputs in which little or no market data exists, which are therefore developed by the Company using estimates and assumptions that reflect those that a market participant would use. The following tables represent the Company’s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2015 and 2014 : As of December 31, 2015 Level 1 Level 2 Level 3 Total Assets: Cash and cash equivalents $ 1,885,826 $ — $ — $ 1,885,826 Short-term investments 13,701,273 — — 13,701,273 Total assets $ 15,587,099 $ — $ — $ 15,587,099 Liabilities: Accrued warrant liability $ — $ — $ 4,048,900 $ 4,048,900 As of December 31, 2014 Level 1 Level 2 Level 3 Total Liabilities: Accrued warrant liability $ — $ — $ 862,074 $ 862,074 Compensatory stock options not yet issued (1) — — 132,295 132,295 Total liabilities $ — $ — $ 994,369 $ 994,369 (1) Included in accrued expenses in the accompanying consolidated balance sheets. The Company has certain warrants that could require settlement in cash if a fundamental transaction occurs, as defined in the respective agreements. These agreements specify the amount due to warrant holders is based on the Black-Scholes pricing model. The following are the assumptions used to measure the accrued warrant liability at December 31, 2015 and 2014 , which were determined in a manner consistent with that described for grants of options to purchase common stock as set forth in Note 2, “Summary of Significant Accounting Policies:" December 31, 2015 2014 Stock Price $ 3.49 $ 5.60 Exercise Price $ 3.00 - 100.00 $ 10.10 - 100.00 Term in years 0.48 - 5.60 0.46 - 6.04 Volatility 64.00 - 114.74% 70.69 - 100.08% Annual rate of quarterly dividends 0 % 0 % Discount rate- bond equivalent yield .31 - 1.86% .12 - 1.65% The following table sets forth a summary of changes in the fair value of the Company’s Level 3 fair value measurements for the years ended December 31, 2015 and 2014 : Year Ended December 31, 2015 Accrued Warrant Liability Compensatory Stock Options Issued After Year End Beginning Balance $ 862,074 $ 132,295 Total (gains) or losses, realized and unrealized, included in earnings (1)(2) 221,915 (51,569 ) Issuances 3,636,260 — Settlements (671,349 ) (80,726 ) Balance at, December 31, 2015 $ 4,048,900 $ — Year Ended December 31, 2014 Accrued Warrant Liability Compensatory Stock Options Issued After Year End Beginning Balance $ 1,241,311 $ 309,450 Total (gains) or losses, realized and unrealized, included in earnings (1)(2) (2,572,035 ) (21,055 ) Issuances 2,283,092 132,295 Settlements (90,294 ) (288,395 ) Balance at, December 31, 2014 $ 862,074 $ 132,295 (1) Unrealized gains or losses related to the accrued warrant liability were included as change in value of accrued warrant liability. For the years ended December 31, 2015 and 2014 we realized gains of $671,349 and $90,294 , respectively, in connection with the elimination of the Series B warrants issued to an investor in the January 2014 equity investment transaction. (2) Expenses recorded for compensatory stock options not yet issued are included in "Research and Development" expense and "General and Administrative" expense in the Statements of Operations. Separate disclosure is required for assets and liabilities measured at fair value on a recurring basis, as documented above, from those measured at fair value on a nonrecurring basis. As of December 31, 2015 and 2014 , the Company had no assets or liabilities that were measured at fair value on a nonrecurring basis. The Company considers the accrued warrant liability and compensatory stock options not yet issued to be Level 3 because some of the inputs into the measurements are neither directly or indirectly observable. The compensatory stock options not yet issued use management’s estimate for the expected term, which is based on the safe harbor method as historical exercise information over the term of each security is not readily available. The following table summarizes the unobservable inputs into the fair value measurements: December 31, 2015 Description Fair Value Valuation Technique Unobservable Input Range in years Accrued warrant liability $ 4,048,900 Black-scholes pricing model Expected term 0.48 - 5.60 Management believes the value of the accrued warrant liability and compensatory stock options are more sensitive to changes in the Company’s stock price at the end of the respective reporting period as opposed to changes in the expected term. At December 31, 2015 , a 10% increase in the expected term of the Company’s warrants measured using the Black-Scholes pricing model would increase the warrant liability by approximately 2% , while a 10% decrease in the expected term would decrease the warrant liability by approximately 2% . A 10% increase in the Company’s stock price would result in an increase in the accrued warrant liability of approximately 13% , while a 10% decrease in the stock price would decrease the warrant liability by approximately 12% . The carrying amounts of the Company’s remaining financial instruments, which include cash, short-term investments, accounts receivable and accounts payable, approximate their fair values due to their short maturities.

Equipment

Equipment	12 Months Ended
	Dec. 31, 2015
Property, Plant and Equipment [Abstract]
Equipment	Equipment The following table summarizes the Company’s gross equipment costs for the years ended December 31, 2015 and 2014 : As of December 31, 2015 2014 Lab equipment $ 298,772 $ 1,062,679 Computer equipment 1,023,795 293,663 Furniture 494,188 528,807 1,816,755 1,885,149 Less accumulated depreciation (1,693,797 ) (1,640,612 ) Equipment, net $ 122,958 $ 244,537 As part of the sublease income received from Buffalo BioLabs, Inc. mentioned in Note 9, Significant Alliances and Related Parties, the Company leases lab equipment to Buffalo BioLabs, Inc. The original cost and net book value of that equipment as of December 31, 2015 was $989,149 and $62,501 , respectively. The monthly income we receive from Buffalo BioLabs, Inc. for this equipment is $4,500 and is cancellable upon 90 days notice.

Noncontrolling Interests

Noncontrolling Interests	12 Months Ended
	Dec. 31, 2015
Noncontrolling Interest [Abstract]
Noncontrolling Interests	Noncontrolling Interests On May 31, 2012, BCV contributed approximately 194.0 million Russian rubles (approximately $5.9 million ) to Incuron, which increased its ownership percentage to 40.78% and decreased CBLI’s ownership percentage to 59.22% , which was the ownership percentage at December 31, 2013 . On June 20, 2014, BCV contributed 100.0 million Russian rubles (approximately $2.9 million ) to Incuron, which increased its ownership interest from 40.78% to 46.06% and decreased CBLI’s ownership percentage from 59.22% to 53.94% . The effect of this change in CBLI’s ownership interest in Incuron on CBLI’s equity is shown on the consolidated statement of stockholders’ equity. On August 5, 2014, BCV contributed an additional 79.9 million Russian rubles (approximately $2.3 million ) to Incuron which increased its ownership interest from 46.06% to 49.98% . On November 25, 2014, BCV exercised their rights under Amendment 1 to the Participation Agreement and purchased 3.05% of Incuron from us for a nominal amount. As a result, effective November 25, 2014 CBLI no longer maintained control of Incuron, owning 46.96% , and deconsolidated Incuron. The Company’s consolidated income statement for the year ended December 31, 2014 includes revenue, research and development, and general and administrative expenses recognized by Incuron through November 25, 2014 in the amounts of $1,000,770 , $1,664,094 and $907,643 , respectively. Beginning on November 25, 2014, CBLI accounted for its ownership interest in Incuron using the equity method of accounting, and recognized its share of equity method losses in the amount of $285,542 by December 31, 2014. The gain on deconsolidation of Incuron amounted to $14,206,555 , and was determined based on comparison of the fair value of CBLI’s retained investment in Incuron of $4,554,000 and the carrying amount of the non-controlling interest on the deconsolidation date of $9,797,083 , less the carrying amount of the net assets of Incuron on the deconsolidation date of $144,528 . The fair value of Incuron at the date of deconsolidation was determined by an independent valuation. This fair value is categorized within Level 3 of the fair value hierarchy. The value was determined by weighting a market approach and an income approach (Risk adjusted debt-free discounted cash flow) using equal weights of 50% and adjusted for uncertainties associated with the Russian capital markets. The unobservable input of the market approach was a 0.5 multiple of market value to invested capital. The unobservable input to the income approach was a discount rate based upon a weighted average cost of capital of 22% . On April 29, 2015, CBLI entered into an agreement to sell its equity stake in Incuron to Dr. Mikhail Mogutov, Chairman of Incuron’s Board of Directors and founder of BCV and/or his designee. The transaction was split into two tranches, with 75% of the Company’s equity stake in Incuron being sold for approximately $3 million on April 29, 2015, and an option being given to Dr. Mogutov to purchase CBLI’s remaining ownership interest in Incuron for approximately $1 million , which was exercised by his affiliate, BCV, on June 30, 2015. The purchase price was paid in the form of (i) $2 million in cash received in April 2015, (ii) the transfer of 264,318 shares of CBLI’s common stock (the " Mogutov Shares "), to escrow which were to be sold with the net proceeds provided to CBLI, and (iii) $1 million in cash paid in July 2015. Consequently, CBLI's remaining cost basis of $906,321 , that resulted from the independent valuation discussed above, was initially recorded as a reduction in equity in the form of treasury stock. By December 31, 2015, 105,418 Mogutov Shares had been sold leaving 158,900 Mogutov Shares with CBLI's escrow agent. As such, $417,545 , representing CBLI's net cash proceeds from the sale of these shares of stock have reduced the treasury stock balance at December 31, 2015. In addition, CBLI assigned its remaining intellectual property relating to Curaxin CBL0137 to Incuron in exchange for a 2% royalty on the future commercialization, licensing or sale of the Curaxin CBL0137 technology. We anticipate that CBLI will continue to provide services to Incuron in a related party capacity following the date of deconsolidation to assist in furthering the development of CBL137. Since the date of the deconsolidation, the Company recognized $881,732 and $154,687 of revenues associated with executed services contracts for the years ended December 31, 2015 and 2014 , respectively. At December 31, 2015 the Company held $135,989 in accounts receivable from Incuron. In 2011 Rusnano, and certain other third-party technology providers formed Panacela to develop and commercialize early-stage drug candidates for the treatment of oncological, infectious or other diseases. CBLI invested $3.0 million , certain third-party owners, assigned and/or provided exclusive licenses, and Rusnano invested $9.0 million , with an additional $17.0 million available for investment. $1.5 million of the $17.0 million was invested in the form of a convertible loan (the “ Panacela Loan ”), discussed in Note 6, “Debt.” By the fourth quarter of 2015 Panacela owed approximately $2.1 million to Rusnano under the Panacela Loan, approximately $0.4 million in trade payables to CBLI and approximately $0.4 million to third-party vendors, for total obligations of approximately $2.9 million . CBLI issued 256,215 shares of common stock to Rusnano, at an agreed-upon valuation of $4.45 per share for an aggregate value of approximately $1.1 million in partial settlement of the obligations due under the Panacela Loan. Then, through a combination of debt-to-equity conversions and cash investment, an additional $1.8 million of equity capital was provided to Panacela in order to retire the remaining obligations. As a result, the Panacela Loan was fully retired, Rusnano’s proportionate equity position remained constant and CBLI’s grew from 60.47% to 66.77% at December 31, 2015 . CBLI issued the 256,215 shares of common stock to Rusnano on December 18, 2015 when the stock closed at a price of $3.73 per share, or $0.72 below the $4.45 per share agreed-upon value, resulting in a gain on debt extinguishment of approximately $184,000 which has been recorded as Interest Other Income in the Statement of Operations for the year ended December 31, 2015.

Debt

Debt	12 Months Ended
	Dec. 31, 2015
Debt Disclosure [Abstract]
Debt	Debt On September 30, 2013, CBLI and BioLab 612 entered into a Loan and Security Agreement (the " Hercules Loan "), with Hercules Technology II, L.P. (" Hercules "), pursuant to which we issued a $6.0 million note and received net proceeds of $5.9 million . During 2015, the Hercules Loan was fully retired. The Hercules Loan bore interest at 10.45% per annum and matured on January 1, 2017, requiring interest-only payments for the initial 12 months and principal and interest payments in 27 monthly installments thereafter. In June 2014, CBLI repaid $4.0 million of the Hercules Loan primarily using net proceeds from a sale of equity intended for this purpose. Between June 2014 and August 2015 CBLI repaid the remaining principal and interest in accordance with the provisions of the Hercules Loan. In August 2015, CBLI fully paid the remaining obligations of the Hercules Loan along with a prepayment penalty of approximately $28,000 and expensed approximately $76,000 in deferred charges. In connection with the Hercules Loan, CBLI granted a first priority lien in substantially all of CBLI’s assets (exclusive of intellectual property) to Hercules. Upon full repayment this lien was cancelled. Additional features of the Hercules Loan, all of which were recorded as debt issuance costs and loan discounts in non-current assets, include: $102,000 related to legal fees and a $100,000 facility fee both of which were paid in cash. A $550,000 “end-of-term charge” which was due and paid upon full repayment of the loan and was included in long-term liabilities. And a 5 -year warrant to purchase 7,813 shares of CBLI common stock. The warrant had an initial exercise price of $32.00 per share, which was subsequently lowered to $10.10 per share in accordance with its terms. The Black-Scholes pricing model yielded $117,999 as the fair value of the warrant upon issuance which was recorded as equity. CBLI amortized the loan discounts and debt issuance costs to interest expense during the term the loan was outstanding using the effective interest rate method, which approximated 16.6% . On September 3, 2013, Panacela entered into the Panacela Loan with Rusnano and CBLI pursuant to which Panacela issued a $1,530,000 note to Rusnano. During 2015 and as noted in Note 5, "Noncontrolling Interests," the Panacela Loan was fully retired. The Panacela Loan bore interest at a rate of 16.3% per annum and matured in September 2015, which was extended into the fourth quarter of 2015. In connection with the Panacela Loan, CBLI issued Rusnano a warrant to purchase shares of CBLI's common stock in the event Panacela defaulted on the Panacela Loan. This warrant was cancelled upon retirement of the Panacela Loan. For the years ended December 31, 2015 and 2014 , we recognized interest expense of $532,049 and $1,340,639 for these loans, respectively. Included in interest expense was $75,907 and $ 401,803 recognized as non-cash reductions of debt issuance costs associated with loan prepayments for the years ended December 31, 2015 and 2014 , respectively.

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2015
Equity [Abstract]
Stockholders' Equity	Stockholders’ Equity On January 27, 2015, the Company’s stockholders approved the Reverse Split of one share for each twenty shares outstanding (1: 20 ). The Reverse Split became effective as of the open of trading on the NASDAQ Capital Market on January 28, 2015. All shares of Common Stock, warrants, options, per share data and exercise prices included in these financial statements and notes for all periods presented have been retroactively adjusted to reflect the Reverse Split with respect to the Company’s shares of Common Stock. As discussed in Note 5, "Noncontrolling Interests," CBLI issued 256,215 shares of common stock to Rusnano, at an agreed-upon value of $4.45 per share for an aggregate value of approximately $1.1 million in partial settlement of the obligations due under the Panacela Loan. The issuance of these shares were recorded at market on the date of issuance, which was $3.73 per share. On July 9, 2015, the Company sold 6,459,948 shares of the Company’s common stock to David Davidovich, a venture capital investor, for an aggregate purchase price of $25.0 million , or $3.87 per share. On February 4, 2015, CBLI entered into a Securities Purchase Agreement with certain institutional investors providing for the issuance and sale of 572,205 registered shares, or the Shares, of the Company’s common stock, at an offering price of $3.00 per share, or the Share Offering, and Series B pre-funded warrants, or the Pre-Funded Warrants, to purchase an aggregate of 594,688 registered shares of its common stock, or the Pre-Funded Warrants Offering. The Share Offering and the Pre-Funded Warrants Offering are referred to collectively as the Offerings. In a concurrent private placement, or the Private Placement Transaction, and, together with the Offerings, CBLI sold to the purchasers of the Shares and Pre-Funded Warrants, 717.4 shares of our Series A Convertible Preferred Stock, stated value of $1,000 per share, or the Preferred Stock, which are convertible into 239,134 shares of our common stock. Gross proceeds from the Offerings amounted to approximately $4.2 million before deducting placement agent fees and expenses. In addition, Series A warrants, or the Series A Warrants, were issued to purchase one share of our common stock for each share of common stock purchased or prefunded in the Offerings and each share of Series A Convertible Preferred Stock purchased in the Private Placement Transaction. The Series A Warrants cover, in the aggregate, 1,406,028 shares of common stock and became exercisable on the six month anniversary of the date of issuance at an exercise price of $3.64 and expire 6 years from the date they become exercisable. The Series A Warrants and Pre-Funded Warrants contain provisions that could require CBLI to settle the warrants in cash, and also provide for price or share issuance adjustments in the event of a subsequent qualified issuance of common stock at a price below $3.64 for the Series A Warrants or $3.00 for the Pre-Funded Warrants, and accordingly have been classified as a liability. As of February 6, 2015, the closing date, the fair value of the Preferred Stock and the Pre-Funded Warrants amounted to $3,636,260 and was determined based on the assumptions using the Black-Scholes valuation model listed below. During 2015, the Pre-Funded Warrants and the Preferred Stock had fully converted into common stock and as such, no balances other than stockholders’ equity remain for these securities. On June 20, 2014, the Company completed a sale of units that were immediately separable into an aggregate of 308,370 shares of the Company’s common stock and warrants to purchase up to 154,186 additional shares of the Company’s common stock issuable upon the exercise of a warrant. Each unit was sold for $11.35 , which qualified as an “at market” transaction as determined by NASDAQ, resulting in net proceeds of approximately $3.4 million after deducting for placement agent fees and offering expenses. In connection with the sale, the Company issued 1,324 warrants to the placement agent. Each warrant has an exercise price of $11.20 per share, and will expire 5 years from the date of issuance. The sale also triggered a reduction in the exercise price of 228,891 of the Company’s warrants to $10.10 . On January 16, 2014, the Company completed a public offering of 286,886 shares of the Company’s common stock at a price of $24.40 per share, resulting in net proceeds of approximately $6.4 million after deducting for placement agent fees and offering expenses. In connection with the offering, the Company issued Series A warrants for 143,445 shares of common stock and Series B warrants for 143,445 shares of common stock to the purchasers. Each Series A warrant has an exercise price of $24.40 per share, and expire five years from the date of issuance. Each Series B warrant has an exercise price of $24.40 per share, and expire 18 months from the date of issuance. In addition to the warrants issued to the purchasers, the Company also issued Series A warrants for an aggregate of 4,306 shares of common stock and Series B warrants for an aggregate of 4,306 shares of common stock to the placement agent as compensation for completing the offering. The warrants to the placement agent have the same terms, including exercise price, as the warrants issued to investors. The offering also triggered a reduction in the exercise price of 221,078 of the Company’s warrants to $24.40 . The January 2014 Series A and B warrants contain provisions that could require the Company to settle the warrants in cash, and accordingly, have been classified as a liability. The fair value of the January Series A and B warrants amounted to $2,283,092 and was determined based on the assumptions using the Black-Scholes valuation model listed below. The following table sets forth the Black-Scholes valuation model assumptions used to value the warrants noted above at the dates indicated: February 6, 2015 Series A Pre-Funded January 16, Stock price $ 3.16 $ 3.16 $ 24.60 Exercise price $ 3.64 $ 3.00 $ 24.40 Term in years 6.5 1.00 .75 - 2.50 Expected volatility 0.83 % 0.88 % 43.06 - 79.86 Expected dividend yield 0 % 0 % 0 % Risk-free interest rate 1.48 % 0.26 % 0.09% - 0.58% On September 4, 2014, the Company and certain investors in the January 16, 2014 public offering discussed above amended the Securities Purchase Agreement to remove restrictions on the Company’s ability to issue securities involving a variable rate transaction, as therein defined. In addition, the same investors returned January 2014 Series B warrants to purchase, in the aggregate, 102,460 shares of the Company’s common stock for cancellation. In exchange for these concessions, the Company agreed to extend the expiration dates from January 16, 2019 to January 16, 2021 for Series A warrants to purchase 102,460 shares of the Company’s common stock, and reduced the exercise price from $24.40 to $20.40 . On September 29, 2014, the Company and certain investors amended a Securities Purchase Agreement, dated as of February 13, 2009, to remove restrictions on the Company’s ability to issue securities involving a variable rate transaction, as therein defined. In exchange, the Company agreed to extend the expiration dates from February 13, 2016 to March 30, 2018 on Series D warrants to purchase 174,307 shares of the Company’s common stock, and revised the anti-dilution provision in the Series D warrants to include variable rate transactions. On January 9, 2015, the Company and certain investors amended a Securities Purchase Agreement, dated as of February 25, 2010, to remove restrictions on the Company’s ability to issue securities involving a variable rate transaction, as therein defined. In exchange, the Company agreed to extend the expiration dates from March 2, 2015 to March 2, 2017 on warrants to purchase shares of the Company’s common stock, and revised the anti-dilution provision to include variable rate transactions. The following table sets forth the changes in the number of warrants outstanding for the periods presented: Number of Warrants Weighted Average Exercise Price Outstanding at December 31, 2013 526,752 $ 54.00 Granted 451,012 19.85 Forfeited, Canceled (102,460 ) 24.40 Outstanding at December 31, 2014 875,304 33.72 Granted 1,406,028 3.64 Exercised (5,077 ) 3.00 Forfeited, Canceled (54,100 ) 36.71 Outstanding at December 31, 2015 2,222,155 13.98 Equity Incentive Plan The following is a summary of option award activity under the Plan for the year ended December 31, 2015 : Year Ended December 31, 2015 Total Stock Options Outstanding Weighted Average Exercise Price per Share Nonvested Stock Options Weighted Average Grant Date Fair Value per Share December 31, 2014 261,389 $ 67.89 21,287 $ 22.31 Granted 131,500 3.19 90,750 2.02 Vested — — (51,287 ) 10.06 Exercised — — — — Forfeited, Canceled (49,246 ) 43.72 (18,750 ) 3.14 December 31, 2015 343,643 46.60 42,000 1.99 The following is a summary of outstanding stock options under the Plan as of December 31, 2015 : Stock Options Outstanding Non-Vested Stock Options Quantity 343,643 42,000 Weighted-average exercise price $ 46.60 $ 3.15 Weighted Average Remaining Contractual Term (in Years) 6.72 9.32 Intrinsic value $ — $ — For the years ended December 31, 2015 , and 2014 , the Company granted 131,500 , and 49,550 stock options, respectively, with a weighted-average grant date fair value of $2.01 , and $7.60 , respectively. For the years ended December 31, 2015 , and 2014 , the total fair value of options vested was $515,904 , and $267,382 , respectively. The total intrinsic value of options exercised for the years ended December 31, 2015 , and 2014 was $0 , and $0 , respectively. As of December 31, 2015 , total compensation cost not yet recognized related to non-vested stock options was $25,529 . The Company expects to recognize this cost over a weighted average period of 0.23 years .

Significant Alliances and Relat

Significant Alliances and Related Parties	12 Months Ended
	Dec. 31, 2015
Related Party Transactions [Abstract]
Significant Alliances and Related Parties	Significant Alliances and Related Parties Roswell Park Cancer Institute The Company has entered into several agreements with Roswell Park Cancer Institute, or RPCI, including: various sponsored research agreements, an exclusive license agreement and clinical trial agreements for the conduct of the Phase 1 entolimod oncology study and the Phase 1 CBL137 intravenous administration study. Additionally, the Company’s Chief Scientific Officer, Dr. Andrei Gudkov, is the Senior Vice President of Basic Research at RPCI. The Company incurred $970,260 , and $1,042,859 in expense to RPCI related to research grants and agreements for the years ended December 31, 2015 , and 2014 , respectively. The Company had $0 and $208,092 included in accounts payable owed to RPCI at December 31, 2015 and 2014 , respectively. In addition, the Company had $183,877 and $324,194 in accrued expenses payable to RPCI at December 31, 2015 and 2014 , respectively. The Cleveland Clinic CBLI entered into an exclusive license agreement, or the License, with The Cleveland Clinic pursuant to which CBLI was granted an exclusive license to The Cleveland Clinic’s research base underlying our therapeutic platform and certain product candidates in development by Panacela. CBLI has the primary responsibility to fund all newly developed patents; however, The Cleveland Clinic retains ownership of those patents covered by the agreement. CBLI also agreed to use commercially diligent efforts to bring one or more products to market as soon as practical, consistent with sound and reasonable business practices and judgments. In consideration for the License, CBLI agreed to issue The Cleveland Clinic common stock and make certain milestone, royalty and sublicense royalty payments. Milestone payments, which may be credited against future royalties, amounted to $0 , and $0 for the years ended December 31, 2015 , and 2014 , respectively. No royalty or sublicense royalty payments were made to The Cleveland Clinic during the two-year period ended December 31, 2015 . The Company also recognized $9,700 , and $0 as research and development expense to CCF for the years ended December 31, 2015 , and 2014 , respectively. The Company had $9,700 and $0 included in accrued expenses payable at December 31, 2015 and 2014 , respectively. Buffalo BioLabs, et. al. Our Chief Scientific Officer, Dr. Andrei Gudkov has business relationships with several entities with which we transact business, the most significant of which is Buffalo BioLabs (" BBL "), where Dr. Gudkov was a founder and currently serves as their Principal Scientific Adviser. Pursuant to a master services agreement we have with BBL, the Company recognized $1,405,261 , and $1,494,464 as research and development expense for the years ended December 31, 2015 , and 2014 , respectively, and included $0 and $54,353 in accounts payable at December 31, 2015 and 2014 . In addition, the Company had $ 87,690 and $9,716 in accrued expenses payable to BBL at December 31, 2015 and 2014 . We also recognized $101,667 , and $230,398 from BBL for sublease and other income for the years ended December 31, 2015 , and 2014 , respectively. Pursuant to our real estate sublease and equipment lease with BBL, we had gross and net accounts receivable of $215,414 and $ 0 at December 31, 2015 and gross and net accounts receivables of $198,124 and $ 88,363 at December 31, 2014 , respectively.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The Company accounts for income taxes using the asset and liability method. Deferred taxes are determined by calculating the future tax consequences attributable to differences between the financial accounting and tax bases of existing assets and liabilities. A valuation allowance is recorded against deferred tax assets when, in the opinion of management, it is more likely than not that the Company will not be able to realize the benefit from its deferred tax assets. The Company files income tax returns, as prescribed by the national, state and local jurisdictions in which it operates. The Company’s uncertain tax positions are related to tax years that remain subject to examination and are recognized in the financial statements when the recognition threshold and measurement attributes are met. Interest and penalties related to tax deficiencies and uncertain tax positions are recorded as income tax expense. Income (loss) from continuing operations consists of the following: For the Year Ended December 31, 2015 2014 US operations $ (9,988,875 ) $ 6,234,092 Foreign operations (3,056,042 ) (6,198,726 ) $ (13,044,917 ) $ 35,366 The provision for income taxes charged to continuing operations is $0 for all periods presented. Deferred tax assets (liabilities) were comprised of the following as of the periods presented below: As of December 31, 2015 2014 Deferred tax assets: Operating loss carryforwards $ 51,710,000 $ 48,643,000 Accrued expenses 8,932,000 8,916,000 Tax credit carryforwards 3,618,000 3,449,000 Intellectual property 3,902,000 3,214,000 Outside tax basis difference in affiliate — 3,948,000 Equipment 330,000 365,000 Other — — Total deferred tax assets 68,492,000 68,535,000 Deferred tax liabilities: — — Net deferred tax asset 68,492,000 68,535,000 Valuation allowance (68,492,000 ) (68,535,000 ) $ — $ — The provision for income taxes differs from the amount of income tax determined by applying the applicable U.S. statutory federal income tax rate to the pretax loss from continuing operations as a result of the following differences: For the Year Ended December 31, 2015 2014 Tax at the U.S. statutory rate $ (4,435,000 ) $ 12,000 Change in value of warrant liability 75,000 (905,000 ) Valuation allowance 3,335,000 5,717,000 Deconsolidation of Incuron — (4,830,000 ) Gain on sale of Incuron 1,020,000 — Other 5,000 6,000 $ — $ — At December 31, 2015 , the Company had U.S. federal net operating loss carryforwards of approximately $128,665,000 , which begin to expire if not utilized by 2023 , and approximately $3,750,000 of tax credit carryforwards which begin to expire if not utilized by 2024. The Company also has state net operating loss carryforwards of approximately $118,097,000 , which begin to expire if not utilized by 2027 and state tax credit carryforwards of approximately $336,000 , which begin to expire if not utilized by 2022 . The purchase of 6,459,948 shares of common stock by Mr. Davidovich on July 9, 2015 resulted in Mr. Davidovich owning 60.2% of the Company, at that time. We therefore believe it highly likely that this transaction, more fully described in Note 7, "Stockholders’ Equity," will be viewed by the U.S. Internal Revenue Service as a change of ownership as defined by Section 382 of the Internal Revenue Code. Consequently, our ability to utilize $124,662,000 of U.S. federal net operating loss carryforwards, $3,642,000 of U.S. tax credit carry forwards, $114,094,000 of state net operating loss carryforwards, and $336,000 of state tax credit carryforwards, all of which occurred prior to July 9, 2015, are limited. As such, a significant portion of these carryforwards will likely expire before they can be utilized, even if the Company is able to generate taxable income that, except for this transaction, would have been sufficient to fully utilize these carryforwards. The Company files U.S. federal tax returns, along with various state and foreign income tax returns. All federal, state and foreign tax returns for the years ended December 31, 2014 , 2013 and 2012 are still open for examination. The following presents a roll-forward of the unrecognized tax benefits and the associated interest and penalties: Unrecognized Tax Benefits Interest and Penalties Balance at January 1, 2014 $ 445,000 $ — Prior year tax position — — Current year tax position — — Deferred tax position 8,000 — Settlements with tax authorities — — Expiration of the statute of limitations — — Balance at December 31, 2014 453,000 — Prior year tax position — — Current year tax position — — Deferred tax position 15,000 — Settlements with tax authorities — — Expiration of the statute of limitations — — Balance at December 31, 2015 $ 468,000 $ — CBLI received New York State incentive tax credit refunds of $119,200 , and $0 during 2015 , and 2014 , respectively. These refundable tax credits were based on the Company’s research and development activities, real estate tax payments, employment levels and equipment purchases. Since there is no state tax liability or refund of prior year tax payments, these refundable tax credits were recorded against operating expenses in the year of receipt, instead of being recorded as an income tax benefit.

Employee Benefit Plan

Employee Benefit Plan	12 Months Ended
	Dec. 31, 2015
Compensation and Retirement Disclosure [Abstract]
Employee Benefit Plan	Employee Benefit Plan CBLI maintains an active defined contribution retirement plan for its employees, referred to herein as the Benefit Plan. All employees satisfying certain service requirements are eligible to participate in the Benefit Plan. The Company makes matching cash contributions each payroll period, up to 4% of employees’ salaries. The Company’s expense relating to the Benefit Plan was $76,668 , and $79,737 for the years ended December 31, 2015 , and 2014 , respectively.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies The Company has entered into various agreements with third parties and certain related parties in connection with the research and development activities of its existing product candidates as well as discovery efforts on potential new product candidates. These agreements include fixed obligations to sponsor research and development activities, minimum royalty payments for licensed patents and additional amounts that may be required upon the achievement of scientific, regulatory and commercial milestones, including milestones such as the submission of an IND to the FDA and the first commercial sale of the Company’s products in various countries. As of December 31, 2015 the Company is uncertain as to whether any of these contingent events will become realized. There were no milestone payments or royalties on net sales accrued for any of these agreements as of December 31, 2015 and 2014 as none were due. From time-to-time, the Company may have certain contingent liabilities that arise in the ordinary course of business. The Company accrues for liabilities when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. For all periods presented, the Company was not a party to any pending material litigation or other material legal proceedings. The Company has entered into agreements with substantially all of our employees who, if terminated by the Company without cause as described in these agreements, would be entitled to severance pay. As of December 31, 2015 , the Company had unconditional purchase obligations totaling $977,860 for goods and services, substantially all of which the Company anticipates to incur during 2016 . Capital Lease In December 2011, the Company entered into a capital lease for scientific equipment in the amount of $304,673 . The terms of the lease required an upfront payment of $82,983 and monthly payments of $7,616 for 36 months once the lease term began in March 2012. Principal payments under the capital lease obligation were $7,522 , and $83,634 ; and, interest payments were $90 , and $7,707 for the years ended December 31, 2015 , and 2014 , respectively. As of December 31, 2015 , accumulated depreciation for the leased equipment was $55,423 . Operating Leases The Company leases laboratory facilities and office facilities at various locations with expiration dates ranging from 2015 to 2019 . The Company recognizes rent expense on a straight-line basis over the term of the related operating leases. For the years ended December 31, 2015 , and 2014 , total rent expense related to the Company’s operating leases was $395,461 , and $511,029 , respectively. In addition, the Company has subleased some of its facilities. As of December 31, 2015 , future minimum payments under operating leases are as follows: 2016 $ 372,420 2017 365,565 2018 376,532 2019 191,048 2020 — Total minimum lease payments $ 1,305,565

Summary of Significant Accoun20

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Basis of Presentation and Consolidation	Basis of Presentation and Consolidation The accompanying consolidated financial statements include the accounts of CBLI and the subsidiaries in which CBLI held a controlling interest as of and for the periods presented. The accounts of Incuron are included through November 25, 2014, the date at which CBLI no longer maintained a controlling interest. For the period from November 25, 2014 through April 29, 2015, the Company’s interest in Incuron has been presented under the equity method of accounting, with the completed sale of our entire equity interests in Incuron recorded in the quarter ended June 30, 2015. All significant intercompany balances and transactions have been eliminated. These financial statements have been prepared on the accrual basis in accordance with accounting principles generally accepted in the United States (" GAAP "). On January 28, 2015, the Company, after receiving authorization from the Company’s shareholders and board of directors, executed a reverse stock split, or Reverse Split, of the Company’s common stock at the ratio of 1:20. All historical share balances and share price-related data have been adjusted based on this ratio.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Cash and Cash Equivalents	Cash and Cash Equivalents Of the $5.9 million and $3.1 million of cash and cash equivalents at December 31, 2015 and December 31, 2014 , respectively, $1.9 million and $0.0 million , respectively, consisted of highly liquid investments with maturities of 90 days or less when purchased. These investments consist of U.S. Treasury securities, time deposits and investments in money market funds with commercial banks and financial institutions. As of December 31, 2015 , $1.2 million of the Company’s cash and cash equivalents were held in Russian banks, of which $1.1 million was denominated in rubles with the remaining $0.1 million denominated in U.S. dollars.
Short-Term Investments	Short-Term Investments The Company’s short-term investments are classified as available for sale. Accordingly, these investments are carried at fair market value. Short-term investments consisted primarily of U.S. Treasury securities. Unrealized gains and losses on available for-sale investments are reported as Other Comprehensive Loss, a separate component of stockholders’ equity. Realized gains and losses, and interest and dividends on available-for-sale securities are recorded in our Consolidated Statement of Operations as "Interest and Other Income." The cost of securities sold is based on the specific identification method. All of the Company's short-term investments were held in U.S. financial institutions.
Concentrations of Credit Risk	Concentrations of Credit Risk Financial instruments that potentially subject the Company to a significant concentration of credit risk primarily consist of cash and cash equivalents and short-term investments. The Company maintains cash balances with financial institutions in excess of insured limits. With the exception of our deposits at NOTA-Bank, discussed in "Restricted Cash" below, the Company does not believe it is exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.
Accounts Receivable	The Company extends unsecured credit to its government customers under normal trade agreements and contracted terms, which generally require payment within 30 days .
Equipment	Equipment Equipment is stated at cost, net of accumulated depreciation. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is credited or charged to operations. Repair and maintenance costs are expensed as incurred. Equipment is depreciated using the straight-line method over the estimated useful lives of the respective assets as follows: Asset Category Estimated Useful Life (in Years) Laboratory equipment 5 Furniture and fixtures 5 Computer equipment 3
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets Long-lived assets to be held and used are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amounts of the assets or related asset group may not be recoverable. Determination of recoverability is based on an estimate of discounted future cash flows resulting from the use of the asset. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the asset or asset group, the carrying amount of the asset is written down to its estimated net realizable value.
Restricted Cash	Restricted Cash Restricted cash at December 31, 2015 includes certificates of deposit denominated in Russian rubles and posted by Panacela and BioLab 612 as collateral for performance guarantees for their contracts with the Ministry of Industry and Trade of the Russian Federation. The guarantees require Panacela and BioLab 612 to satisfactorily perform their statements of work under the contracts, after which the requirement for these deposits will be released. Both Panacela and BioLab 612 anticipate satisfactory contract performance with the release of funds processed in 2017. As a consequence, all of the Company’s restricted cash is classified as a noncurrent asset.
Equity Method Investments	Equity Method Investment The Company’s equity method investment, reported as of December 31, 2014, included its minority holdings in Incuron. The opening equity investment amount as of November 25, 2014, the date at which we no longer maintained a controlling interest, was determined to be $4,554,000 and represented an ownership interest in Incuron of 46.96% . This determination was made by an independent valuation expert based on the commercial potential of Incuron’s drug candidates and market values assigned to other early-stage oncology drug candidates. Under the equity method, the carrying amount of the investment is adjusted for the Company’s share of earnings and losses, as well as any capital contributions to and distributions from Incuron. The Company classifies income and losses related to its equity method investments as a component of operating income or loss as Incuron is an extension of the Company’s core business.
Intellectual Property	Intellectual Property Costs related to filing and pursuing patent applications are recognized as general and administrative expenses as incurred, since the recoverability of such expenditures is uncertain. Upon marketability approval by the U.S. Food and Drug Administration (" FDA "), or a respective foreign governing body, such costs will be capitalized and depreciated over the expected life of the related patent.
Deferred Revenue	Deferred Revenue Deferred revenue represents cash received under grants and contracts in excess of the revenue recognizable through the end of the respective financial reporting period. The revenue associated with these advances will be recognized in future periods as the applicable costs are incurred.
Accrued Warrant Liability	Accrued Warrant Liability Certain warrants are accounted for as derivative instruments in accordance with the Financial Accounting Standards Board Accounting Standards Codification (the " Codification "), on derivatives and hedging as the warrant holders, under certain change of control situations, could require settlement in cash. As such, the warrants were initially recorded as liabilities based on their fair values on the date of issuance. Subsequent changes in the value of the warrants are recorded in the Statements of Operations as “Change in value of warrant liability.” The Company’s remaining outstanding warrants were treated as equity upon issuance and continue to be treated as equity since they did not contain any mandatory redemption features or other provisions that would require a different classification of these warrant instruments outside of permanent equity.
Foreign Currency Translation	Foreign Currency Translation The Russian ruble is the functional currency of our foreign subsidiaries, which are all located in the Russian Federation. Assets and liabilities of these companies are translated into U.S. dollars at the period-end exchange rate. Income and expense items are translated at the average exchange rates during the period. The net effect of this translation is recorded in the consolidated financial statements as accumulated other comprehensive income (loss).
Other Comprehensive Income/(Loss)	Other Comprehensive Income/(Loss) The Company applies the Codification on comprehensive income (loss) that requires disclosure of all components of comprehensive income (loss) on an annual and interim basis. Comprehensive income (loss) is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. The following table presents the changes in accumulated other comprehensive loss for the year ended December 31, 2015 . Unrealized loss on available-for-sale securities Gains and losses on foreign exchange translations Total Beginning balance $ — $ (380,110 ) $ (380,110 ) Other comprehensive income/(loss) before reclassifications (6,190 ) 30,025 23,835 Amounts reclassified from accumulated other comprehensive loss — (51,776 ) (51,776 ) Ending balance $ (6,190 ) $ (401,861 ) $ (408,051 )
Revenue Recognition	Revenue Recognition The Company generates grant and contract revenue from two different types of contractual arrangements: cost reimbursable grants and contracts and fixed-price grants and contracts. Costs consist primarily of internal labor charges, subcontractors and materials, as well as an allocation of fringe benefits, overhead and general and administrative expenses, based on the terms of the contract. Under cost reimbursable grants and contracts, revenue is recognized during the period that the associated research and development costs are incurred. Under fixed-price grants and contracts, revenue is recognized using the percentage-of-completion method. The assumptions and estimates used in determination of the percentage-of-completion are developed in coordination with the principal investigator performing the work.
Research and Development	Research and Development Research and development (" R&D ") costs are expensed as incurred. R&D costs primarily consist of salaries, fringe benefits, and stock-based compensation for our clinical and scientific personnel along with a ratable share of our facility expenses. Other R&D expenses include fees paid to research-oriented consultants and outside service providers, and the costs of materials used in clinical trials and other research activities.
Accounting for Stock-Based Compensation	Accounting for Stock-Based Compensation The 2006 Equity Incentive Plan, as amended (the “ Plan ”), authorizes CBLI to grant (i) options to purchase common stock, (ii) restricted or unrestricted stock units, and (iii) stock appreciation rights, so long as the exercise or grant price of each are at least equal to the fair market value of the stock on the date of grant. At the 2015 annual meeting of stockholders, an amendment to increase the maximum number of shares of common stock reserved for issuance under the Plan was approved, and as of December 31, 2015 , an aggregate of 650,000 shares of common stock were authorized for issuance under the Plan, of which a total of approximately 180,476 shares of common stock remained available for future awards. A single participant cannot be awarded more than 100,000 shares annually. Awards granted under the Plan have a contractual life of no more than 10 years . The terms and conditions of equity awards (such as price, vesting schedule, term and number of shares) under the Plan are specified in an award document, and approved by compensation committee of the CBLI board of directors. The Company utilizes the Black-Scholes valuation model for estimating the fair value of all stock options granted. Set forth below are the assumptions used in valuing the stock options granted and a discussion of the Company’s methodology for developing each of the assumptions used: For the year ended December 31, 2015 2014 Risk-free interest rate 1.35-1.59% 1.59 - 1.98% Expected dividend yield 0% 0% Expected life 5 - 5.5 Years 5 - 6 Years Expected volatility 75.53-76.21% 71.24 - 78.02% “Risk-free interest rate” means the range of U.S. Treasury rates with a term that most closely resembles the expected life of the option as of the date the option is granted. “Expected dividend yield” means the Company does not pay regular dividends on its common stock and does not anticipate paying any dividends in the foreseeable future. “Expected life” means the period of time that options granted are expected to remain outstanding, based wholly on the use of the simplified (safe harbor) method. The simplified method is used because the Company does not yet have adequate historical exercise information to estimate the expected life the options granted. “Expected volatility” means a measure of the amount by which a financial variable, such as share price, has fluctuated (historical volatility) or is expected to fluctuate (implied volatility) during a period. Expected volatility is based on the Company’s historical volatility and incorporates the volatility of the common stock of comparable companies when the expected life of the option exceeds the Company’s trading history. In June 2013, CBLI’s stockholders approved the 2013 Employee Stock Purchase Plan (" ESPP "), which provides a means by which eligible employees of CBLI, and certain designated related corporations may be given an opportunity to purchase shares of CBLI common stock. As of December 31, 2015 , there were 225,000 shares of common stock reserved for purchase under the ESPP. The number of shares reserved for purchase under the ESPP increases on January 1 of each calendar year by the lesser of (i) 10% of the total number of shares of common stock outstanding on December 31 of the preceding year, or (ii) 100,000 shares of common stock. The ESPP, when implemented, will allow employees to use up to 15% of their compensation, up to $25,000 per year, to purchase shares of common stock at an amount equal to 85% of the fair market value of the our common stock on the offering date or the purchase date, whichever is less.
Income Taxes	Income taxes No income tax expense was recorded for the years ended December 31, 2015 , and 2014 , as the Company did not have taxable income for any of the years presented. A full valuation allowance has been recorded against the Company’s net deferred tax asset.
Earnings (Loss) per Share	Earnings/(loss) per share Basic net income (loss) per share of common stock excludes dilution for potential common stock issuances and is computed by dividing net income (loss) by the weighted average number of shares outstanding for the period. Diluted net income (loss) per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock. Diluted net loss per share is identical to basic net loss per share as potentially dilutive securities have been excluded from the calculation of diluted net loss per common share because the inclusion of such securities would be antidilutive. The Company has excluded the following outstanding warrants and options from the calculation of diluted net loss per share because all such securities were antidilutive for the periods presented: As of December 31, Common Equivalent Securities 2015 2014 Warrants 2,222,155 875,304 Options 343,643 261,389 Total 2,565,798 1,136,693
Recent Accounting Pronouncements	Recently Issued Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board or other standard setting bodies that are adopted by us as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our financial position or results of operations upon adoption. In January 2016, the FASB issued ASU 2016-01, "Financial Instruments - Overall: Recognition and Measurement of Financial Assets and Financial Liabilities." The pronouncement requires equity investments (except those accounted for under the equity method of accounting, or those that result in consolidation of the investee) to be measured at fair value with changes in fair value recognized in net income, requires public business entities to use the exit price notion when measuring the fair value of financial instruments for disclosure purposes, requires separate presentation of financial assets and financial liabilities by measurement category and form of financial asset, and eliminates the requirement for public business entities to disclose the method(s) and significant assumptions used to estimate the fair value that is required to be disclosed for financial instruments measured at amortized cost. These changes become effective for the Company's fiscal year beginning January 1, 2018. The expected adoption method of ASU 2016-01 is being evaluated by the Company and the adoption is not expected to have a significant impact on the Company’s consolidated financial position or results of operations. In May 2015, the FASB issued ASU 2015-08, Business Combinations - Pushdown Accounting - Amendment to SEC Paragraphs Pursuant to Staff Accounting Bulletin No. 115. This Update was issued to amend various SEC paragraphs pursuant to the issuance of Staff Accounting Bulletin No. 115. This ASU is not expected to have a significant impact on the Company’s financial statements. In November 2014, the FASB issued ASU 2014-17, Business Combinations (Topic 805): Pushdown Accounting. The amendments in this Update apply to the separate financial statements of an acquired entity and its subsidiaries that are a business or nonprofit activity (either public or nonpublic) upon the occurrence of an event in which an acquirer (an individual or an entity) obtains control of the acquired entity. An acquired entity may elect the option to apply pushdown accounting in the reporting period in which the change-in-control event occurs. If pushdown accounting is not applied in the reporting period in which the change-in-control event occurs, an acquired entity will have the option to elect to apply pushdown accounting in a subsequent reporting period to the acquired entity's most recent change-in-control event. The amendments in this Update were effective on November 18, 2014. After the effective date, an acquired entity can make an election to apply the guidance to future change-in-control events or to its most recent change-in-control event. This ASU is not expected to have a significant impact on the Company’s financial statements. In May 2014, the Financial Accounting Standards Board (" FASB "), issued Accounting Standards Update (" ASU, 2014-9 "), Revenue from Contracts with Customers, which updates the principles for recognizing revenue. ASU 2014-9 also amends the required disclosures of the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. ASU 2014-9 is effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. The Company is evaluating the potential impacts of the new standard on its existing revenue recognition policies and procedures. In August 2014, the FASB issued ASU 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (" ASU 2014-15 ") requires that an entity’s management evaluate whether there are conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued. ASU 2014-15 is effective for annual periods beginning after December 15, 2016 and for interim periods thereafter. The Company is evaluating the potential impacts of this new standard on its quarterly reporting process.

Summary of Significant Accoun21

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Revenue by Customer	The following table presents our revenue by customer, on a proportional basis, for the periods indicated: Years ended December 31, 2015 2014 Variance U.S. Department of Defense 7.9 % 0.6 % 7.3 % Russian government agencies 59.6 % 95.2 % (35.6 )% Incuron, LLC 32.5 % 4.2 % 28.3 % 100.0 % 100.0 % — %
Property, Plant, and Equipment Useful Lives	Equipment is depreciated using the straight-line method over the estimated useful lives of the respective assets as follows: Asset Category Estimated Useful Life (in Years) Laboratory equipment 5 Furniture and fixtures 5 Computer equipment 3
Changes in Accumulated Other Comprehensive Income (Loss)	The following table presents the changes in accumulated other comprehensive loss for the year ended December 31, 2015 . Unrealized loss on available-for-sale securities Gains and losses on foreign exchange translations Total Beginning balance $ — $ (380,110 ) $ (380,110 ) Other comprehensive income/(loss) before reclassifications (6,190 ) 30,025 23,835 Amounts reclassified from accumulated other comprehensive loss — (51,776 ) (51,776 ) Ending balance $ (6,190 ) $ (401,861 ) $ (408,051 )
Summary of Assumptions Used in Valuing Stock Options Granted	The Company utilizes the Black-Scholes valuation model for estimating the fair value of all stock options granted. Set forth below are the assumptions used in valuing the stock options granted and a discussion of the Company’s methodology for developing each of the assumptions used: For the year ended December 31, 2015 2014 Risk-free interest rate 1.35-1.59% 1.59 - 1.98% Expected dividend yield 0% 0% Expected life 5 - 5.5 Years 5 - 6 Years Expected volatility 75.53-76.21% 71.24 - 78.02%
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The Company has excluded the following outstanding warrants and options from the calculation of diluted net loss per share because all such securities were antidilutive for the periods presented: As of December 31, Common Equivalent Securities 2015 2014 Warrants 2,222,155 875,304 Options 343,643 261,389 Total 2,565,798 1,136,693

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2015
Fair Value Disclosures [Abstract]
Fair Value Hierarchy for Financial Assets and Liabilities Measured on Recurring Basis	The following tables represent the Company’s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2015 and 2014 : As of December 31, 2015 Level 1 Level 2 Level 3 Total Assets: Cash and cash equivalents $ 1,885,826 $ — $ — $ 1,885,826 Short-term investments 13,701,273 — — 13,701,273 Total assets $ 15,587,099 $ — $ — $ 15,587,099 Liabilities: Accrued warrant liability $ — $ — $ 4,048,900 $ 4,048,900 As of December 31, 2014 Level 1 Level 2 Level 3 Total Liabilities: Accrued warrant liability $ — $ — $ 862,074 $ 862,074 Compensatory stock options not yet issued (1) — — 132,295 132,295 Total liabilities $ — $ — $ 994,369 $ 994,369 (1) Included in accrued expenses in the accompanying consolidated balance sheets.
Schedule of Share-Based Payment Award Warrant Liability Valuation Assumptions	The following are the assumptions used to measure the accrued warrant liability at December 31, 2015 and 2014 , which were determined in a manner consistent with that described for grants of options to purchase common stock as set forth in Note 2, “Summary of Significant Accounting Policies:" December 31, 2015 2014 Stock Price $ 3.49 $ 5.60 Exercise Price $ 3.00 - 100.00 $ 10.10 - 100.00 Term in years 0.48 - 5.60 0.46 - 6.04 Volatility 64.00 - 114.74% 70.69 - 100.08% Annual rate of quarterly dividends 0 % 0 % Discount rate- bond equivalent yield .31 - 1.86% .12 - 1.65%
Summary of Changes in Fair Value of Company's Level 3 Fair Value Measurements	The following table sets forth a summary of changes in the fair value of the Company’s Level 3 fair value measurements for the years ended December 31, 2015 and 2014 : Year Ended December 31, 2015 Accrued Warrant Liability Compensatory Stock Options Issued After Year End Beginning Balance $ 862,074 $ 132,295 Total (gains) or losses, realized and unrealized, included in earnings (1)(2) 221,915 (51,569 ) Issuances 3,636,260 — Settlements (671,349 ) (80,726 ) Balance at, December 31, 2015 $ 4,048,900 $ — Year Ended December 31, 2014 Accrued Warrant Liability Compensatory Stock Options Issued After Year End Beginning Balance $ 1,241,311 $ 309,450 Total (gains) or losses, realized and unrealized, included in earnings (1)(2) (2,572,035 ) (21,055 ) Issuances 2,283,092 132,295 Settlements (90,294 ) (288,395 ) Balance at, December 31, 2014 $ 862,074 $ 132,295 (1) Unrealized gains or losses related to the accrued warrant liability were included as change in value of accrued warrant liability. For the years ended December 31, 2015 and 2014 we realized gains of $671,349 and $90,294 , respectively, in connection with the elimination of the Series B warrants issued to an investor in the January 2014 equity investment transaction. (2) Expenses recorded for compensatory stock options not yet issued are included in "Research and Development" expense and "General and Administrative" expense in the Statements of Operations.
Summary of Unobservable Inputs in Fair Value Measurements	The following table summarizes the unobservable inputs into the fair value measurements: December 31, 2015 Description Fair Value Valuation Technique Unobservable Input Range in years Accrued warrant liability $ 4,048,900 Black-scholes pricing model Expected term 0.48 - 5.60

Equipment (Tables)

Equipment (Tables)	12 Months Ended
	Dec. 31, 2015
Property, Plant and Equipment [Abstract]
Summary of Equipment Costs	The following table summarizes the Company’s gross equipment costs for the years ended December 31, 2015 and 2014 : As of December 31, 2015 2014 Lab equipment $ 298,772 $ 1,062,679 Computer equipment 1,023,795 293,663 Furniture 494,188 528,807 1,816,755 1,885,149 Less accumulated depreciation (1,693,797 ) (1,640,612 ) Equipment, net $ 122,958 $ 244,537

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2015
Equity [Abstract]
Assumptions Used to Measure the Compensatory Stock Options	The following table sets forth the Black-Scholes valuation model assumptions used to value the warrants noted above at the dates indicated: February 6, 2015 Series A Pre-Funded January 16, Stock price $ 3.16 $ 3.16 $ 24.60 Exercise price $ 3.64 $ 3.00 $ 24.40 Term in years 6.5 1.00 .75 - 2.50 Expected volatility 0.83 % 0.88 % 43.06 - 79.86 Expected dividend yield 0 % 0 % 0 % Risk-free interest rate 1.48 % 0.26 % 0.09% - 0.58%
Schedule of Stockholders' Equity Note, Warrants or Rights	The following table sets forth the changes in the number of warrants outstanding for the periods presented: Number of Warrants Weighted Average Exercise Price Outstanding at December 31, 2013 526,752 $ 54.00 Granted 451,012 19.85 Forfeited, Canceled (102,460 ) 24.40 Outstanding at December 31, 2014 875,304 33.72 Granted 1,406,028 3.64 Exercised (5,077 ) 3.00 Forfeited, Canceled (54,100 ) 36.71 Outstanding at December 31, 2015 2,222,155 13.98
Summary of Option Award Activity	The following is a summary of option award activity under the Plan for the year ended December 31, 2015 : Year Ended December 31, 2015 Total Stock Options Outstanding Weighted Average Exercise Price per Share Nonvested Stock Options Weighted Average Grant Date Fair Value per Share December 31, 2014 261,389 $ 67.89 21,287 $ 22.31 Granted 131,500 3.19 90,750 2.02 Vested — — (51,287 ) 10.06 Exercised — — — — Forfeited, Canceled (49,246 ) 43.72 (18,750 ) 3.14 December 31, 2015 343,643 46.60 42,000 1.99
Summary of Outstanding Stock Options	The following is a summary of outstanding stock options under the Plan as of December 31, 2015 : Stock Options Outstanding Non-Vested Stock Options Quantity 343,643 42,000 Weighted-average exercise price $ 46.60 $ 3.15 Weighted Average Remaining Contractual Term (in Years) 6.72 9.32 Intrinsic value $ — $ —

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Schedule of Income (Loss) from Continuing Operations before Income Tax, Domestic and Foreign	Income (loss) from continuing operations consists of the following: For the Year Ended December 31, 2015 2014 US operations $ (9,988,875 ) $ 6,234,092 Foreign operations (3,056,042 ) (6,198,726 ) $ (13,044,917 ) $ 35,366
Schedule of Deferred Tax Assets (Liabilities)	Deferred tax assets (liabilities) were comprised of the following as of the periods presented below: As of December 31, 2015 2014 Deferred tax assets: Operating loss carryforwards $ 51,710,000 $ 48,643,000 Accrued expenses 8,932,000 8,916,000 Tax credit carryforwards 3,618,000 3,449,000 Intellectual property 3,902,000 3,214,000 Outside tax basis difference in affiliate — 3,948,000 Equipment 330,000 365,000 Other — — Total deferred tax assets 68,492,000 68,535,000 Deferred tax liabilities: — — Net deferred tax asset 68,492,000 68,535,000 Valuation allowance (68,492,000 ) (68,535,000 ) $ — $ —
Schedule of Effective Income Tax Rate Reconciliation	The provision for income taxes differs from the amount of income tax determined by applying the applicable U.S. statutory federal income tax rate to the pretax loss from continuing operations as a result of the following differences: For the Year Ended December 31, 2015 2014 Tax at the U.S. statutory rate $ (4,435,000 ) $ 12,000 Change in value of warrant liability 75,000 (905,000 ) Valuation allowance 3,335,000 5,717,000 Deconsolidation of Incuron — (4,830,000 ) Gain on sale of Incuron 1,020,000 — Other 5,000 6,000 $ — $ —
Summary of Unrecognized Tax Benefits and the Associated Interest and Penalties	The following presents a roll-forward of the unrecognized tax benefits and the associated interest and penalties: Unrecognized Tax Benefits Interest and Penalties Balance at January 1, 2014 $ 445,000 $ — Prior year tax position — — Current year tax position — — Deferred tax position 8,000 — Settlements with tax authorities — — Expiration of the statute of limitations — — Balance at December 31, 2014 453,000 — Prior year tax position — — Current year tax position — — Deferred tax position 15,000 — Settlements with tax authorities — — Expiration of the statute of limitations — — Balance at December 31, 2015 $ 468,000 $ —

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Lease Payments for Operating Leases	As of December 31, 2015 , future minimum payments under operating leases are as follows: 2016 $ 372,420 2017 365,565 2018 376,532 2019 191,048 2020 — Total minimum lease payments $ 1,305,565

Description of Business (Detail

Description of Business (Detail)	12 Months Ended
	Dec. 31, 2015Subsidiary
BioLab 612
Subsidiary or Equity Method Investee [Line Items]
Number of wholly-owned subsidiaries	1

Summary of Significant Accoun28

Summary of Significant Accounting Policies - Basis of Presentation (Details)	Jan. 28, 2015
Accounting Policies [Abstract]
Reverse stock split ratio	0.05

Summary of Significant Accoun29

Summary of Significant Accounting Policies - Cash and Cash Equivalents (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Cash and Cash Equivalents [Line Items]
Cash and cash equivalents	$ 5,918,424	$ 3,103,969	$ 10,048,466
Cash equivalents	$ 1,900,000	$ 0
Cash and highly liquid investments maturity	90 days
Russian Federation
Cash and Cash Equivalents [Line Items]
Cash and cash equivalents	$ 1,200,000
Russian Rubles | Russian Federation
Cash and Cash Equivalents [Line Items]
Cash and cash equivalents	1,100,000
US Dollars | Russian Federation
Cash and Cash Equivalents [Line Items]
Cash and cash equivalents	$ 100,000

Summary of Significant Accoun30

Summary of Significant Accounting Policies - Concentrations of Credit Risk (Details) - USD ($)	Dec. 31, 2015	Feb. 12, 2015	Dec. 31, 2015	Dec. 31, 2014
Product Information [Line Items]
Cash and Cash Equivalents, Period Increase (Decrease)		$ (87,100)	$ 2,814,455	$ (6,944,497)
Minimum
Product Information [Line Items]
Russian Ruble : Dollar Exchange Rate	$ 72.8827		$ 72.8827
Maximum
Product Information [Line Items]
Russian Ruble : Dollar Exchange Rate		$ 79.1144
Outside of the U.S. | Geographic Concentration Risk | Cash and Cash Equivalents Located Outside the US
Product Information [Line Items]
Concentration risk percentage	21.00%

Summary of Significant Accoun31

Summary of Significant Accounting Policies - Significant Customers and Accounts Receivable (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Concentration Risk [Line Items]
Allowance for doubtful accounts receivable	$ 0.2	$ 0.1
Customer Concentration Risk | Sales Revenue, Services, Net
Concentration Risk [Line Items]
Concentration risk percentage	100.00%	100.00%
Increase (decrease) in concentration risk percentage	0.00%
Customer Concentration Risk | Sales Revenue, Services, Net | U.S. Department of Defense
Concentration Risk [Line Items]
Concentration risk percentage	7.90%	0.60%
Increase (decrease) in concentration risk percentage	7.30%
Customer Concentration Risk | Sales Revenue, Services, Net | Russian government agencies
Concentration Risk [Line Items]
Concentration risk percentage	59.60%	95.20%
Increase (decrease) in concentration risk percentage	(35.60%)
Customer Concentration Risk | Sales Revenue, Services, Net | Incuron, LLC
Concentration Risk [Line Items]
Concentration risk percentage	32.50%	4.20%
Increase (decrease) in concentration risk percentage	28.30%
Customer Concentration Risk | Accounts Receivable
Concentration Risk [Line Items]
Credit term	30 days

Summary of Significant Accoun32

Summary of Significant Accounting Policies - Equipment (Detail)	12 Months Ended
	Dec. 31, 2015
Laboratory equipment
Property, Plant and Equipment [Line Items]
Estimated Useful Life (in Years)	5 years
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Estimated Useful Life (in Years)	5 years
Computer equipment
Property, Plant and Equipment [Line Items]
Estimated Useful Life (in Years)	3 years

Summary of Significant Accoun33

Summary of Significant Accounting Policies - Restricted Cash (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Accounting Policies [Abstract]
Value of deposits written off with NOTA-Bank	$ 1,060,834	$ 0

Summary of Significant Accoun34

Summary of Significant Accounting Policies - Equity Method Investment (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014	Nov. 25, 2014
Schedule of Equity Method Investments [Line Items]
Investment in Incuron, LLC	$ 0	$ 4,268,458
Incuron, LLC
Schedule of Equity Method Investments [Line Items]
Investment in Incuron, LLC			$ 4,554,000
Ownership interest in Incuron			46.96%

Summary of Significant Accoun35

Summary of Significant Accounting Policies - Other Comprehensive Income/(Loss) (Details)	12 Months Ended
	Dec. 31, 2015USD ($)
AOCI Including Portion Attributable to Noncontrolling Interest [Abstract]
Beginning balance	$ (380,110)
Other comprehensive income/(loss) before reclassifications	23,835
Amounts reclassified from accumulated other comprehensive loss	(51,776)
Ending balance	(408,051)
Unrealized loss on available-for-sale securities
AOCI Including Portion Attributable to Noncontrolling Interest [Abstract]
Beginning balance	0
Other comprehensive income/(loss) before reclassifications	(6,190)
Amounts reclassified from accumulated other comprehensive loss	0
Ending balance	(6,190)
Gains and losses on foreign exchange translations
AOCI Including Portion Attributable to Noncontrolling Interest [Abstract]
Beginning balance	(380,110)
Other comprehensive income/(loss) before reclassifications	30,025
Amounts reclassified from accumulated other comprehensive loss	(51,776)
Ending balance	$ (401,861)

Summary of Significant Accoun36

Summary of Significant Accounting Policies - Revenue Recognition (Details)	12 Months Ended
	Dec. 31, 2015Agreement
Accounting Policies [Abstract]
Number of contractual arrangement	2

Summary of Significant Accoun37

Summary of Significant Accounting Policies - Accounting for Stock-Based Compensation (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected dividend yield	0.00%	0.00%
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	0.31%	0.12%
Expected life	5 months 23 days	5 months 16 days
Expected volatility	64.00%	70.69%
Minimum | Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	1.35%	1.59%
Expected life	5 years	5 years
Expected volatility	75.53%	71.24%
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	1.86%	1.65%
Expected life	5 years 7 months 6 days	6 years 15 days
Expected volatility	114.74%	100.08%
Maximum | Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	1.59%	1.98%
Expected dividend yield	0.00%	0.00%
Expected life	5 years 6 months	6 years
Expected volatility	76.21%	78.02%
2006 Equity Incentive Plan (The Plan)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares of common stock authorized under 2006 Equity Incentive Plan (in shares)	650,000
Number of authorized common stock shares (in shares)	180,476
Maximum amount of shares a single participant can be awarded annually (in shares)	100,000
Contractual life of awards granted under 2006 Equity Incentive Plan	10 years
2013 ESPP Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of authorized common stock shares (in shares)	225,000
Percentage of the total number of shares of common stock outstanding of the preceding year	10.00%
Maximum amount of shares of common stock that employee can purchase per year (in shares)	100,000
Maximum percentage of annual compensation that employee can use to purchase common stock shares	15.00%
Maximum amount employee can spend to purchase common stock shares	$ 25,000
Percent of fair maket value that common stock can be purchased at	85.00%

Summary of Significant Accoun38

Summary of Significant Accounting Policies - Income taxes (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Accounting Policies [Abstract]
Income tax expense (benefit)	$ 0	$ 0	$ 0

Summary of Significant Accoun39

Summary of Significant Accounting Policies - Earnings/(loss) per share (Detail) - shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common Equivalent Securities	2,565,798	1,136,693
Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common Equivalent Securities	2,222,155	875,304
Options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common Equivalent Securities	343,643	261,389

Fair Value Measurements - Fair

Fair Value Measurements - Fair Value Hierarchy for Financial Assets and Liabilities Measured on Recurring Basis (Detail) - USD ($)	Dec. 31, 2015	Feb. 06, 2015	Dec. 31, 2014	Jan. 16, 2014
Liabilities:
Accrued warrant liability	$ 4,048,900	$ 3,636,260	$ 862,074	$ 2,283,092
Recurring
Assets:
Cash and cash equivalents	1,885,826
Short-term investments	13,701,273
Assets:	15,587,099
Liabilities:
Compensatory stock options not yet issued			132,295
Total liabilities			994,369
Recurring | Level 1
Assets:
Cash and cash equivalents	1,885,826
Short-term investments	13,701,273
Assets:	15,587,099
Liabilities:
Compensatory stock options not yet issued			0
Total liabilities			0
Recurring | Level 2
Assets:
Cash and cash equivalents	0
Short-term investments	0
Assets:	0
Liabilities:
Compensatory stock options not yet issued			0
Total liabilities			0
Recurring | Level 3
Assets:
Cash and cash equivalents	0
Short-term investments	0
Assets:	0
Liabilities:
Compensatory stock options not yet issued			132,295
Total liabilities			994,369
Warrants | Recurring
Liabilities:
Accrued warrant liability	4,048,900		862,074
Warrants | Recurring | Level 1
Liabilities:
Accrued warrant liability	0		0
Warrants | Recurring | Level 2
Liabilities:
Accrued warrant liability	0		0
Warrants | Recurring | Level 3
Liabilities:
Accrued warrant liability	$ 4,048,900		$ 862,074

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Share-Based Payment Award Warrant Liability Valuation Assumptions (Detail) - $ / shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Jun. 20, 2014	Jan. 16, 2014
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Stock price (in dollars per share)	$ 3.49	$ 5.60	$ 11.35	$ 24.40
Annual rate of quarterly dividends	0.00%	0.00%
Minimum
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Exercise price	$ 3	$ 10.10
Term in years	5 months 23 days	5 months 16 days
Volatility	64.00%	70.69%
Discount rate-bond equivalent yield	0.31%	0.12%
Maximum
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Exercise price	$ 100	$ 100
Term in years	5 years 7 months 6 days	6 years 15 days
Volatility	114.74%	100.08%
Discount rate-bond equivalent yield	1.86%	1.65%

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Changes in Fair Value of Company's Level 3 Fair Value Measurements (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Series B Pre-funded Warrants
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Realized gains (losses)	$ 671,349	$ 90,294
Accrued Warrant Liability
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	862,074	1,241,311
Total (gains) or losses, realized and unrealized, included in earnings	221,915	(2,572,035)
Issuances	3,636,260	2,283,092
Settlements	(671,349)	(90,294)
Ending balance	4,048,900	862,074
Compensatory Stock Options Issued After Year End
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	132,295	309,450
Total (gains) or losses, realized and unrealized, included in earnings	(51,569)	(21,055)
Issuances	0	132,295
Settlements	(80,726)	(288,395)
Ending balance	$ 0	$ 132,295

Fair Value Measurements - Sum43

Fair Value Measurements - Summary of Unobservable Inputs into Fair Value Measurement for Accrued Warrant Liability (Detail) - Accrued Warrant Liability - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Fair Value	$ 4,048,900	$ 862,074	$ 1,241,311
Valuation Technique	Black-scholes pricing model
Unobservable Input	Expected term
Percentage increase in expected term	10.00%
Percentage increase in warrant liability with increase in expected term	2.00%
Percentage decrease in expected term	10.00%
Percentage decrease in warrant liability with decrease in expected term	2.00%
Percentage increase in stock price	10.00%
Percentage increase in warrant liability with increase in stock price	13.00%
Percentage decrease in stock price	10.00%
Percentage decrease in warrant liability with decrease in stock price	12.00%
Minimum
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Range in years	5 months 23 days
Maximum
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Range in years	5 years 7 months 6 days

Equipment - Summary of Equipmen

Equipment - Summary of Equipment Costs (Detail) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Property, Plant and Equipment [Line Items]
Property, plant, and equipment	$ 1,816,755	$ 1,885,149
Less accumulated depreciation	(1,693,797)	(1,640,612)
Equipment, net	122,958	244,537
Lab equipment
Property, Plant and Equipment [Line Items]
Property, plant, and equipment	298,772	1,062,679
Computer equipment
Property, Plant and Equipment [Line Items]
Property, plant, and equipment	1,023,795	293,663
Furniture
Property, Plant and Equipment [Line Items]
Property, plant, and equipment	$ 494,188	$ 528,807

Equipment - Additional Informat

Equipment - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Property, Plant and Equipment [Line Items]
Cost of equipment	$ 1,816,755	$ 1,885,149
Net book value of equipment	122,958	$ 244,537
Buffalo BioLabs
Property, Plant and Equipment [Line Items]
Cost of equipment	989,149
Net book value of equipment	62,501
Buffalo BioLabs | Equipment
Property, Plant and Equipment [Line Items]
Monthly income from lease equipment	$ 4,500
Lease cancellable notice period	90 days

Noncontrolling Interests - Incu

Noncontrolling Interests - Incuron (Detail) RUB in Millions	Apr. 29, 2015USD ($)tranche	Nov. 25, 2014USD ($)	Aug. 05, 2014USD ($)	Aug. 05, 2014RUB	Jun. 20, 2014USD ($)	Jun. 20, 2014RUB	May. 31, 2012USD ($)	May. 31, 2012RUB	Jul. 31, 2015USD ($)	Dec. 31, 2014USD ($)shares	Nov. 25, 2014USD ($)	Dec. 31, 2015USD ($)shares	Dec. 31, 2014USD ($)shares	Aug. 04, 2015	Jun. 19, 2014
Noncontrolling Interest [Line Items]
General and administrative expense												$ 7,143,293	$ 9,654,144
Research and development expense												6,355,962	8,469,690
Income (loss) in equity method investment												(362,137)	(285,542)
Gain on deconsolidation												0	14,206,555
Investment in Incuron, LLC										$ 4,268,458		0	4,268,458
Non-controlling interest on deconsolidation													$ 11,396,710
Repurchase of Treasury Stock												$ 906,321
Sale of treasury stock (shares) | shares												105,418
Treasury stock, (shares) | shares										0		158,900	0
Net proceeds from sale of treasury stock												$ 417,545	$ 0
Incuron, LLC
Noncontrolling Interest [Line Items]
Ownership percentage by noncontrolling owners			49.98%	49.98%	46.06%	46.06%	40.78%	40.78%						46.06%	40.78%
Ownership percentage by parent					53.94%	53.94%	59.22%	59.22%							59.22%
Ownership interest in Incuron		46.96%									46.96%
Revenue											$ 1,000,770
General and administrative expense											1,664,094
Research and development expense											907,643
Income (loss) in equity method investment										$ (285,542)
Gain on deconsolidation		$ 14,206,555
Investment in Incuron, LLC		4,554,000									$ 4,554,000
Non-controlling interest on deconsolidation		9,797,083
Carrying amount of net assets		$ 144,528
Revenue from related parties												881,732	$ 154,687
Accounts receivable related parties												$ 135,989
Incuron, LLC | Bioprocess Capital Ventures
Noncontrolling Interest [Line Items]
Sale number of tranches | tranche	2
Equity method investment ownership sold	75.00%
Equity method investment amount sold	$ 3,000,000
Equity method investment remaining fund committed	1,000,000
Equity method investment sales proceeds	$ 2,000,000								$ 1,000,000
Treasury stock number of shares held (in shares) | shares												264,318
Percentage of royalty exchanged												2.00%
Incuron, LLC | Market Approach Valuation Technique | Level 3
Noncontrolling Interest [Line Items]
Weights used in calculating risk adjusted debt-free discounted cash flow for determining fair value of Incuron, Market approach												50.00%
Unobservable input of the market approach as a multiple of market value to invested capital												0.5
Incuron, LLC | Income Approach Valuation Technique | Level 3
Noncontrolling Interest [Line Items]
Weights used in calculating risk adjusted debt-free discounted cash flow for determining fair value of Incuron, Income approach												50.00%
Unobservable input to the income approach, based on discount rate based upon a weighted average cost of capital												22.00%
Bioprocess Capital Ventures | Incuron, LLC
Noncontrolling Interest [Line Items]
Payments to acquire additional interest in subsidiaries			$ 2,300,000	RUB 79.9	$ 2,900,000	RUB 100	$ 5,900,000	RUB 194
Percentage of voting interest acquired		3.05%									3.05%

Noncontrolling Interests - Pana

Noncontrolling Interests - Panacela (Details) - USD ($)	Dec. 18, 2015	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2011	Sep. 30, 2015	Jun. 20, 2014	Jan. 16, 2014	Sep. 03, 2013
Noncontrolling Interest [Line Items]
Long-term debt		$ 0	$ 1,499,050
Liabilities		5,842,752	8,028,130
Debt to equity conversion		$ 1,846,200	$ 0
Stock price (in dollars per share)		$ 3.49	$ 5.60			$ 11.35	$ 24.40
Gain on debt extinguishment		$ 184,475	$ 0
Panacela Loan
Noncontrolling Interest [Line Items]
Debt instrument face amount								$ 1,530,000
Panacela
Noncontrolling Interest [Line Items]
Payments to acquire interest in subsidiary				$ 3,000,000
Ownership percentage by parent		66.77%			60.47%
Panacela | Panacela Loan
Noncontrolling Interest [Line Items]
Debt instrument face amount								$ 1,500,000
Converted debt shares issued (in shares)	256,215
Converted debt, conversion price (in dollars per share)	$ 4.45
Debt to equity conversion	$ 1,100,000
Debt to equity conversion	$ 1,800,000
Stock price (in dollars per share)	$ 3.73
Convertible debt beneficial conversion feature share price (in dollars per share)	$ 0.72
Gain on debt extinguishment		$ 184,000
Panacela
Noncontrolling Interest [Line Items]
Liabilities		2,900,000
Panacela | Cleveland BioLabs, Inc
Noncontrolling Interest [Line Items]
Accounts payable		400,000
Panacela | Rusnano
Noncontrolling Interest [Line Items]
Long-term debt		2,100,000
Panacela | Third-Party Vendors
Noncontrolling Interest [Line Items]
Other liabiltiies		$ 400,000
Rusnano | Panacela
Noncontrolling Interest [Line Items]
Payments to acquire interest in subsidiary				9,000,000
Investment amount available				$ 17,000,000

Debt (Detail)

Debt (Detail) - USD ($)	Sep. 30, 2013	Aug. 31, 2015	Jun. 30, 2014	Dec. 31, 2015	Dec. 31, 2014	Sep. 04, 2014	Jun. 20, 2014	Jan. 16, 2014	Sep. 03, 2013
Debt Instrument [Line Items]
Non cash write off, debt issuance cost				$ 75,907	$ 401,803
Number of securities called by warrants							154,186
Exercise price of warrants (in dollars per share)						$ 20.40	$ 10.10	$ 24.40
Interest expense				532,049	$ 1,340,639
Hercules Loan
Debt Instrument [Line Items]
Debt instrument face amount	$ 6,000,000
Proceeds from notes payable	$ 5,900,000
Stated interest rate	10.45%
Frequency of interest only payment	12 months
Frequency of principal and interest payment	27 months
Early repayment of debt			$ 4,000,000
Repayment of long-term debt		$ 28,000		550,000
Non cash write off, debt issuance cost		$ 76,000
Legal fees				102,000
Facility fees				$ 100,000
Warrant term				5 years
Number of securities called by warrants				7,813
Exercise price of warrants (in dollars per share)	$ 32			$ 10.10
Fair value of warrants issued in connection with debt				$ 117,999
Debt effective percentage				16.60%
Panacela Loan
Debt Instrument [Line Items]
Debt instrument face amount									$ 1,530,000
Debt stated rate									16.30%

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail)	Dec. 18, 2015USD ($)$ / sharesshares	Jul. 09, 2015USD ($)$ / sharesshares	Feb. 04, 2015USD ($)$ / sharesshares	Jan. 28, 2015	Sep. 29, 2014shares	Sep. 04, 2014$ / sharesshares	Jun. 20, 2014USD ($)$ / sharesshares	Jan. 16, 2014USD ($)$ / sharesshares	Dec. 31, 2015USD ($)$ / sharesshares	Dec. 31, 2014USD ($)$ / sharesshares	Feb. 06, 2015USD ($)shares
Class of Stock [Line Items]
Reverse stock split ratio				0.05
Stock price (in dollars per share) | $ / shares							$ 11.35	$ 24.40	$ 3.49	$ 5.60
Stock issued during period (in shares)							308,370	286,886
Offering costs | $									$ 28,880,473	$ 9,802,118
Exercise price of warrants (in dollars per share) | $ / shares						$ 20.40	$ 10.10	$ 24.40
Proceeds from issuance of common stock | $							$ 3,400,000	$ 6,400,000	$ 27,190,292	$ 9,697,501
Number of warrants adjusted due to reduction in exercise price							228,891	221,078
Options grants in period (in shares)									131,500	49,550
Number of securities called by warrants							154,186
Accrued warrant liability | $								$ 2,283,092	$ 4,048,900	$ 862,074	$ 3,636,260
Options grants in period, weighted-average grant date fair value (in dollars per share) | $ / shares									$ 2.01	$ 7.60
Options vested in period, fair value | $									$ 515,904	$ 267,382
Options exercised in period intrinsic value | $									$ 0	$ 0
Common Stock
Class of Stock [Line Items]
Stock issued during period (in shares)			572,205						8,122,189	595,256
Offering costs | $									$ 40,611	$ 2,976
Shares issued price per share (in dollars per share) | $ / shares			$ 3
Purchasers
Class of Stock [Line Items]
Exercise price of warrants (in dollars per share) | $ / shares							$ 11.20
Warrants expiration period from the date of issuance							5 years
Placement Agent
Class of Stock [Line Items]
Number of securities called by warrants							1,324
Investor
Class of Stock [Line Items]
Stock issued during period (in shares)		6,459,948
Offering costs | $		$ 25,000,000
Shares issued price per share (in dollars per share) | $ / shares		$ 3.87
Series A Preferred Stock | Preferred Stock
Class of Stock [Line Items]
Stock issued during period (in shares)			717.4
Shares issued price per share (in dollars per share) | $ / shares			$ 1,000
Aggregate share issued upon conversion (in shares)			239,134
Gross proceeds from issuance of Series A Convertible Preferred Stock | $			$ 4,200,000
Series B Pre-funded Warrants
Class of Stock [Line Items]
Exercise price of warrants (in dollars per share) | $ / shares			$ 3
Common stock shares , repurchase						102,460
Number of securities called by warrants			594,688
Series A
Class of Stock [Line Items]
Warrants issued during period new issues			1,406,028
Exercise price of warrants (in dollars per share) | $ / shares			$ 3.64
Warrants expiration period from the date of issuance			6 years
Common stock shares , repurchase						102,460
Series A | Common Stock
Class of Stock [Line Items]
Number of securities called by each warrant (in share)			1
Series A | Purchasers
Class of Stock [Line Items]
Exercise price of warrants (in dollars per share) | $ / shares								$ 24.40
Warrants expiration period from the date of issuance								5 years
Number of securities called by warrants								143,445
Series A | Placement Agent
Class of Stock [Line Items]
Number of securities called by warrants								4,306
Series A | Series A Preferred Stock | Preferred Stock
Class of Stock [Line Items]
Number of securities called by each warrant (in share)											1
Series B | Purchasers
Class of Stock [Line Items]
Exercise price of warrants (in dollars per share) | $ / shares								$ 24.40
Warrants expiration period from the date of issuance								18 months
Number of securities called by warrants								143,445
Series B | Placement Agent
Class of Stock [Line Items]
Number of securities called by warrants								4,306
Series D
Class of Stock [Line Items]
Common stock shares , repurchase					174,307
Panacela | Panacela Loan
Class of Stock [Line Items]
Converted debt shares issued (in shares)	256,215
Converted debt, conversion price (in dollars per share) | $ / shares	$ 4.45
Debt to equity conversion | $	$ 1,100,000
Stock price (in dollars per share) | $ / shares	$ 3.73

Stockholders' Equity - Summary

Stockholders' Equity - Summary of Assumptions Used in Valuing Warrants (Detail) - $ / shares	Feb. 06, 2015	Jan. 16, 2014	Dec. 31, 2015	Dec. 31, 2014	Feb. 04, 2015	Sep. 04, 2014	Jun. 20, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock price (in dollars per share)		$ 24.40	$ 3.49	$ 5.60			$ 11.35
Exercise price of warrants (in dollars per share)		24.40				$ 20.40	$ 10.10
Expected dividend yield			0.00%	0.00%
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Term in years			5 months 23 days	5 months 16 days
Expected volatility			64.00%	70.69%
Risk-free interest rate			0.31%	0.12%
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Term in years			5 years 7 months 6 days	6 years 15 days
Expected volatility			114.74%	100.08%
Risk-free interest rate			1.86%	1.65%
Black Scholes Stock Price Valuation Model
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock price (in dollars per share)		24.60
Exercise price of warrants (in dollars per share)		$ 24.40
Expected dividend yield		0.00%
Black Scholes Stock Price Valuation Model | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Term in years		9 months
Expected volatility		43.06%
Risk-free interest rate		0.09%
Black Scholes Stock Price Valuation Model | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Term in years		2 years 6 months
Expected volatility		79.86%
Risk-free interest rate		0.58%
Series A
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price of warrants (in dollars per share)					$ 3.64
Series A | Black Scholes Stock Price Valuation Model
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock price (in dollars per share)	$ 3.16
Exercise price of warrants (in dollars per share)	$ 3.64
Term in years	6 years 6 months
Expected volatility	0.83%
Expected dividend yield	0.00%
Risk-free interest rate	1.48%
Series B Pre-funded Warrants
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price of warrants (in dollars per share)					$ 3
Series B Pre-funded Warrants | Black Scholes Stock Price Valuation Model
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock price (in dollars per share)	$ 3.16
Exercise price of warrants (in dollars per share)	$ 3
Term in years	1 year
Expected volatility	0.88%
Expected dividend yield	0.00%
Risk-free interest rate	0.26%

Stockholders' Equity - Schedule

Stockholders' Equity - Schedule of Stockholders' Equity Note, Warrants or Rights (Detail) - Warrants - $ / shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Number of Warrants:
Number of Warrants Outstanding, Beginning balance (in shares)	875,304	526,752
Number of Warrants, Granted (in shares)	1,406,028	451,012
Number of Warrants, Exercised (in shares)	(5,077)
Number of Warrants, Forfeited, Canceled (in shares)	(54,100)	(102,460)
Number of Warrants Outstanding, Ending balance (in shares)	2,222,155	875,304
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Weighted Average Exercise Price, Outstanding, Beginning balance (in dollars per share)	$ 33.72	$ 54
Weighted Average Exercise Price, Granted (in dollars per share)	3.64	19.85
Weighted Average Exercise Price, Exercised (in dollars per share)	3
Weighted Average Exercise Price, Forfeited, Canceled (in dollars per share)	36.71	24.40
Weighted Average Exercise Price, Outstanding, Ending balance (in dollars per share)	$ 13.98	$ 33.72

Stockholders' Equity - Summar52

Stockholders' Equity - Summary of Option Award Activity (Detail) - $ / shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Total Stock Options Outstanding:
Total Stock Options Outstanding, Beginning balance (in shares)	261,389
Total Stock Options Outstanding, Granted (in shares)	131,500	49,550
Total Stock Options Outstanding, Exercised (in shares)	0
Total Stock Options Outstanding, Forfeited, Canceled (in shares)	(49,246)
Total Stock Options Outstanding, Ending balance (in shares)	343,643	261,389
Weighted Average Exercise Price per Share:
Weighted Average Exercise Price per Share, Beginning balance (in dollars per share)	$ 67.89
Weighted Average Exercise Price per Share, Granted (in dollars per share)	3.19
Weighted Average Exercise Price per Share, Exercised (in dollars per share)	0
Weighted Average Exercise Price per Share, Forfeited, Canceled (in dollars per share)	43.72
Weighted Average Exercise Price per Share, Ending balance (in dollars per share)	$ 46.60	$ 67.89
Nonvested Stock Options:
Nonvested Stock Options, Beginning balance (in shares)	21,287
Nonvested Stock Options, Granted (in shares)	90,750
Nonvested Stock Options, Vested (in shares)	(51,287)
Nonvested Stock Options, Forfeited, Canceled (in shares)	(18,750)
Nonvested Stock Options, Ending balance (in shares)	42,000	21,287
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Weighted Average Grant Date Fair Value per Share, Beginning balance (in dollars per share)	$ 22.31
Weighted Average Grant Date Fair Value per Share, Granted (in dollars per share)	2.02
Weighted Average Grant Date Fair Value per Share, Vested (in dollars per share)	10.06
Weighted Average Grant Date Fair Value per Share, Forfeited, Canceled (in dollars per share)	3.14
Weighted Average Grant Date Fair Value per Share, Ending balance (in dollars per share)	$ 1.99	$ 22.31

Stockholders' Equity - Summar53

Stockholders' Equity - Summary of Outstanding Stock Options (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Options Outstanding, Quantity (in shares)	343,643	261,389
Stock Options Outstanding, Weighted-average exercise price (in dollars per share)	$ 46.60	$ 67.89
Nonvested Stock Options, Quantity (in shares)	42,000	21,287
Options Additional Information:
Options grants in period (in shares)	131,500	49,550
Options grants in period, weighted-average grant date fair value (in dollars per share)	$ 2.01	$ 7.60
Options vested in period, fair value	$ 515,904	$ 267,382
Options exercised in period intrinsic value	$ 0	$ 0
Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Options Outstanding, Quantity (in shares)	343,643
Stock Options Outstanding, Weighted-average exercise price (in dollars per share)	$ 46.60
Stock Options Outstanding, Weighted Average Remaining Contractual Term (in Years)	6 years 8 months 19 days
Stock Options Outstanding, Intrinsic value	$ 0
Nonvested Stock Options, Quantity (in shares)	42,000
Nonvested Stock Options, Weighted-average exercise price (in dollars per share)	$ 3.15
Nonvested Stock Options, Weighted Average Remaining Contractual Term (in Years)	9 years 3 months 26 days
Nonvested Stock Options, Intrinsic value	$ 0
Options Additional Information:
Compensation cost not yet recognized related to non-vested stock options	$ 25,529
Compensation cost not yet recognized, period for recognition	2 months 23 days

Significant Alliances and Rel54

Significant Alliances and Related Parties (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Related Party Transaction [Line Items]
Research and development expense	$ 7,143,293	$ 9,654,144
Accounts payable owed	197,134	1,057,743
R P C I
Related Party Transaction [Line Items]
Expense related to research grants and agreements	970,260	1,042,859
Accounts payable owed	0	208,092
Accrued expenses payable	183,877	324,194
Cleveland Clinic
Related Party Transaction [Line Items]
Expense related to research grants and agreements	9,700	0
Accrued expenses payable	9,700	0
Milestone payments credited against future royalties	0	0
Royalty or sublicense royalty payments	0
Buffalo BioLabs
Related Party Transaction [Line Items]
Accounts payable owed	0	54,353
Accrued expenses payable	87,690	9,716
Research and development expense	1,405,261	1,494,464
Sublease and other income from BBL	101,667	230,398
Accounts receivable related parties, gross	215,414	198,124
Accounts receivable related parties	$ 0	$ 88,363

Income Taxes - Schedule of Inco

Income Taxes - Schedule of Income (Loss) from Continuing Operations before Income Tax, Domestic and Foreign (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest [Abstract]
US operations	$ (9,988,875)	$ 6,234,092
Foreign operations	(3,056,042)	(6,198,726)
Total	$ (13,044,917)	$ 35,366

Income Taxes - Schedule of Defe

Income Taxes - Schedule of Deferred Tax Assets (Liabilities) (Detail) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Deferred tax assets:
Operating loss carryforwards	$ 51,710	$ 48,643
Accrued expenses	8,932	8,916
Tax credit carryforwards	3,618	3,449
Intellectual property	3,902	3,214
Outside tax basis difference in affiliate	0	3,948
Equipment	330	365
Other	0	0
Total deferred tax assets	68,492	68,535
Deferred tax liabilities:	0	0
Net deferred tax asset	68,492	68,535
Valuation allowance	(68,492)	(68,535)
Net deferred tax asset	$ 0	$ 0

Income Taxes - Schedule of Effe

Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Effective Income Tax Rate Reconciliation, Amount [Abstract]
Tax at the U.S. statutory rate	$ (4,435,000)	$ 12,000
Change in value of warrant liability	75,000	(905,000)
Valuation allowance	3,335,000	5,717,000
Deconsolidation of Incuron	0	(4,830,000)
Gain on sale of Incuron	1,020,000	0
Other	5,000	6,000
Total	$ 0	$ 0	$ 0

Income Taxes - Summary of Unrec

Income Taxes - Summary of Unrecognized Tax Benefits and the Associated Interest and Penalties (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Unrecognized Tax Benefits
Beginning balance, Unrecognized tax benefits	$ 453,000	$ 445,000
Prior year tax position	0	0
Current year tax position	0	0
Deferred tax position	15,000	8,000
Settlements with tax authorities	0	0
Expiration of the statute of limitations	0	0
Ending balance, Unrecognized tax benefits	468,000	453,000
Interest and Penalties
Beginning balance, Interest and penalties	0	0
Prior year tax position	0	0
Current year tax position	0	0
Deferred tax position	0	0
Settlements with tax authorities	0	0
Expiration of the statute of limitations	0	0
Ending balance at December, Interest and penalties	$ 0	$ 0

Income Taxes - Additional infor

Income Taxes - Additional information (Detail) - USD ($)	Jul. 09, 2015	Jun. 20, 2014	Jan. 16, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Income Tax Disclosure [Abstract]
Income tax expense (benefit)				$ 0	$ 0	$ 0
Operating Loss Carryforwards [Line Items]
Stock issued during period (in shares)		308,370	286,886
NEW YORK
Operating Loss Carryforwards [Line Items]
Proceeds from income tax refunds				119,200	$ 0
U.S. federal
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards				128,665,000
Tax credit carryforward				3,750,000
Operating loss carryforward limitations on use				124,662,000
Tax credit carryforward limitiations on use				3,642,000
State and Local Jurisdiction
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards				118,097,000
Tax credit carryforward				336,000
Operating loss carryforward limitations on use				114,094,000
Tax credit carryforward limitiations on use				$ 336,000
Investor
Operating Loss Carryforwards [Line Items]
Stock issued during period (in shares)	6,459,948
Investor ownership percentage of company	60.20%

Employee Benefit Plan - Additio

Employee Benefit Plan - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Compensation and Retirement Disclosure [Abstract]
Maximum percentage of employees' paycheck that company matches	4.00%
Expense relating to the Benefit Plan	$ 76,668	$ 79,737

Commitments and Contingencies -

Commitments and Contingencies - Schedule of Future Minimum Lease Payments for Operating Leases (Detail)	Dec. 31, 2015USD ($)
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]
2,016	$ 372,420
2,017	365,565
2,018	376,532
2,019	191,048
2,020	0
Total minimum lease payments	$ 1,305,565

Commitments and Contingencies62

Commitments and Contingencies - Additional Information (Detail) - USD ($)	1 Months Ended	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2015	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Milestone payment & royalties		$ 0	$ 0
Unconditional purchase obligation		977,860
Capital lease obligations	$ 304,673
Upfront payment	82,983
Capital lease monthly payment	$ 7,616
Capital lease term	36 months
Debt instrument, periodic payment		7,522	83,634
Debt instrument, periodic payment, interest		90	7,707
Accumulated depreciation for leased equipment		55,423
Operating leases, rent expense		$ 395,461	$ 511,029